Recent years have witnessed a renewed interest in the pathogenic mechanisms of amyotrophic lateral sclerosis (ALS), a late-onset progressive degeneration of motor neurons. The discovery of new genes associated with the familial form of the disease, along with a deeper insight into pathways already described for this disease, has led scientists to reconsider previous postulates. While protein misfolding, mitochondrial dysfunction, oxidative damage, defective axonal transport, and excitotoxicity have not been dismissed, they need to be re-examined as contributors to the onset or progression of ALS in the light of the current knowledge that the mutations of proteins involved in RNA processing, apparently unrelated to the previous “old partners,” are causative of the same phenotype. Thus, newly envisaged models and tools may offer unforeseen clues on the etiology of this disease and hopefully provide the key to treatment. Antioxid. Redox Signal. 17, 1277–1330.
AbalkhailH, MitchellJ, HabgoodJ, OrrellR, de BellerocheJ. A new familial amyotrophic lateral sclerosis locus on chromosome 16q12.1-16q12.2. Am J Hum Genet, 73:383–389. 2003.
2.
[ACTSG] ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology, 46:1244–1249. 1996.
3.
AebischerJ, CassinaP, OtsmaneB, MoumenA, SeilheanD, MeiningerV, BarbeitoL, PettmannB, RaoulC. IFNgamma triggers a LIGHT-dependent selective death of motoneurons contributing to the non-cell-autonomous effects of mutant SOD1. Cell Death Differ, 18:754–768. 2011.
4.
AggarwalS, CudkowiczM. ALS drug development: reflections from the past and a way forward. Neurotherapeutics, 5:516–527. 2008.
5.
AggarwalSP, ZinmanL, SimpsonE, McKinleyJ, JacksonKE, PintoH, KaufmanP, ConwitRA, SchoenfeldD, ShefnerJ, CudkowiczM. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol, 9:481–488. 2010.
6.
AguirreN, BealMF, MatsonWR, BogdanovMB. Increased oxidative damage to DNA in an animal model of amyotrophic lateral sclerosis. Free Radic Res, 39:383–388. 2005.
7.
AiroldiG, GuidarelliA, CantoniO, PanzeriC, VantaggiatoC, BonatoS, Grazia D'AngeloM, FalconeS, De PalmaC, TonelliA, CrimellaC, BondioniS, BresolinN, ClementiE, BassiMT. Characterization of two novel SETX mutations in AOA2 patients reveals aspects of the pathophysiological role of senataxin. Neurogenetics, 11:91–100. 2010.
8.
Al-ChalabiA, ShawPJ, YoungCA, MorrisonKE, MurphyC, ThornhillM, KellyJ, SteenIN, LeighPN. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008–006891-31]BMC Neurol, 11:111. 2011.
9.
Al-SaifA, Al-MohannaF, BohlegaS. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol, 70:913–919. 2011.
10.
AllenMJ, LacroixJJ, RamachandranS, CaponeR, WhitlockJL, GhadgeGD, ArnsdorfMF, RoosRP, LalR. Mutant SOD1 forms ion channel: implications for ALS pathophysiology. Neurobiol Dis, 45:831–838. 2011.
11.
AlmondSL, FradleyRL, ArmstrongEJ, HeavensRB, RutterAR, NewmanRJ, ChiuCS, KonnoR, HutsonPH, BrandonNJ. Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia. Mol Cell Neurosci, 32:324–334. 2006.
12.
AnderssonMK, StahlbergA, ArvidssonY, OlofssonA, SembH, StenmanG, NilssonO, AmanP. The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biol, 9:37. 2008.
13.
AnheimM, Lagier-TourenneC, StevaninG, FleuryM, DurrA, NamerIJ, DenoraP, BriceA, MandelJL, KoenigM, TranchantC. SPG11 spastic paraplegia. A new cause of juvenile parkinsonism. J Neurol, 256:104–108. 2009.
14.
AppelSH, BeersDR, HenkelJS. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?Trends Immunol, 31:7–17. 2010.
15.
AppelSH, ZhaoW, BeersDR, HenkelJS. The microglial-motoneuron dialogue in ALS. Acta Myol, 30:4–8. 2011.
16.
AquilanoK, VigilanzaP, RotilioG, CirioloMR. Mitochondrial damage due to SOD1 deficiency in SH-SY5Y neuroblastoma cells: a rationale for the redundancy of SOD1. Faseb J, 20:1683–1685. 2006.
17.
AraiT, HasegawaM, AkiyamaH, IkedaK, NonakaT, MoriH, MannD, TsuchiyaK, YoshidaM, HashizumeY, OdaT. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun, 351:602–611. 2006.
18.
ArcielloM, CapoCR, CozzolinoM, FerriA, NenciniM, CarriMT, RossiL. Inactivation of cytochrome c oxidase by mutant SOD1s in mouse motoneuronal NSC-34 cells is independent from copper availability but is because of nitric oxide. J Neurochem, 112:183–192. 2010.
19.
AshPE, ZhangYJ, RobertsCM, SaldiT, HutterH, BurattiE, PetrucelliL, LinkCD. Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum Mol Genet, 19:3206–3218. 2010.
20.
AtkinJD, FargMA, TurnerBJ, TomasD, LysaghtJA, NunanJ, RembachA, NagleyP, BeartPM, CheemaSS, HorneMK. Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1. J Biol Chem, 281:30152–30165. 2006.
21.
AtkinJD, FargMA, WalkerAK, McLeanC, TomasD, HorneMK. Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis. Neurobiol Dis, 30:400–407. 2008.
22.
AudetJN, GowingG, JulienJP. Wild-type human SOD1 overexpression does not accelerate motor neuron disease in mice expressing murine Sod1 G86R. Neurobiol Dis, 40:245–250. 2010.
23.
AyalaYM, De ContiL, Avendano-VazquezSE, DhirA, RomanoM, D'AmbrogioA, TollerveyJ, UleJ, BaralleM, BurattiE, BaralleFE. TDP-43 regulates its mRNA levels through a negative feedback loop. Embo J, 30:277–288. 2011.
24.
AzzouzM, HottingerA, PaternaJC, ZurnAD, AebischerP, BuelerH. Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2. Hum Mol Genet, 9:803–811. 2000.
25.
BabstM, KatzmannDJ, Estepa-SabalEJ, MeerlooT, EmrSD. Escrt-III: an endosome-associated heterooligomeric protein complex required for mvb sorting. Dev Cell, 3:271–282. 2002.
26.
BabstM, KatzmannDJ, SnyderWB, WendlandB, EmrSD. Endosome-associated complex, ESCRT-II, recruits transport machinery for protein sorting at the multivesicular body. Dev Cell, 3:283–289. 2002.
27.
BabuJR, GeethaT, WootenMW. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem, 94:192–203. 2005.
28.
BanksGT, KutaA, IsaacsAM, FisherEM. TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander. Mamm Genome, 19:299–305. 2008.
29.
BarberSC, ShawPJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med, 48:629–641. 2010.
30.
BarbosaLF, CerqueiraFM, MacedoAF, GarciaCC, AngeliJP, SchumacherRI, SogayarMC, AugustoO, CarriMT, Di MascioP, MedeirosMH. Increased SOD1 association with chromatin, DNA damage, p53 activation, and apoptosis in a cellular model of SOD1-linked ALS. Biochim Biophys Acta, 1802:462–471. 2010.
31.
BassoM, MassignanT, SamengoG, CheroniC, De BiasiS, SalmonaM, BendottiC, BonettoV. Insoluble mutant SOD1 is partly oligoubiquitinated in amyotrophic lateral sclerosis mice. J Biol Chem, 281:33325–33335. 2006.
32.
BassoM, SamengoG, NardoG, MassignanT, D'AlessandroG, TartariS, CantoniL, MarinoM, CheroniC, De BiasiS, GiordanaMT, StrongMJ, EstevezAG, SalmonaM, BendottiC, BonettoV. Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS One, 4:e8130. 2009.
33.
BatleviY, La SpadaAR. Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging. Neurobiol Dis, 43:46–51. 2011.
34.
BeckM, FlacheneckerP, MagnusT, GiessR, ReinersK, ToykaKV, NaumannM. Autonomic dysfunction in ALS: a preliminary study on the effects of intrathecal BDNF. Amyotroph Lateral Scler Other Motor Neuron Disord, 6:100–103. 2005.
35.
BeghiE, ChioA, CouratierP, EstebanJ, HardimanO, LogroscinoG, MillulA, MitchellD, PreuxPM, PupilloE, StevicZ, SwinglerR, TraynorBJ, Van den BergLH, VeldinkJH, ZoccolellaS. The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler, 12:1–10. 2011.
36.
BellinghamMC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?CNS Neurosci Ther, 17:4–31. 2011.
37.
BenatarM. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis, 26:1–13. 2007.
38.
BendottiC, CarriMT. Lessons from models of SOD1-linked familial ALS. Trends Mol Med, 10:393–400. 2004.
39.
BendottiC, TortaroloM, SuchakSK, CalvaresiN, CarvelliL, BastoneA, RizziM, RattrayM, MenniniT. Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J Neurochem, 79:737–746. 2001.
40.
BensimonG, LacomblezL, MeiningerV. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med, 330:585–591. 1994.
41.
BerettaS, SalaG, MattavelliL, CeresaC, CasciatiA, FerriA, CarriMT, FerrareseC. Mitochondrial dysfunction due to mutant copper/zinc superoxide dismutase associated with amyotrophic lateral sclerosis is reversed by N-acetylcysteine. Neurobiol Dis, 13:213–221. 2003.
42.
BergemalmD, ForsbergK, JonssonPA, GraffmoKS, BrannstromT, AndersenPM, AnttiH, MarklundSL. Changes in the spinal cord proteome of an amyotrophic lateral sclerosis murine model determined by differential in-gel electrophoresis. Mol Cell Proteomics, 8:1306–1317. 2009.
43.
BergemalmD, ForsbergK, SrivastavaV, GraffmoKS, AndersenPM, BrannstromT, WingsleG, MarklundSL. Superoxide dismutase-1 and other proteins in inclusions from transgenic amyotrophic lateral sclerosis model mice. J Neurochem, 114:408–418. 2010.
44.
BergemalmD, JonssonPA, GraffmoKS, AndersenPM, BrannstromT, RehnmarkA, MarklundSL. Overloading of stable and exclusion of unstable human superoxide dismutase-1 variants in mitochondria of murine amyotrophic lateral sclerosis models. J Neurosci, 26:4147–4154. 2006.
45.
BertolottiA, MelotT, AckerJ, VigneronM, DelattreO, ToraL. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes. Mol Cell Biol, 18:1489–1497. 1998.
46.
BilslandLG, SahaiE, KellyG, GoldingM, GreensmithL, SchiavoG. Deficits in axonal transport precede ALS symptoms in vivo. Proc Natl Acad Sci U S A, 107:20523–20528. 2010.
47.
BlauwHM, Al-ChalabiA, AndersenPM, van VughtPW, DiekstraFP, van EsMA, SarisCG, GroenEJ, van RheenenW, KoppersM, Van't SlotR, StrengmanE, EstradaK, RivadeneiraF, HofmanA, UitterlindenAG, KiemeneyLA, VermeulenSH, BirveA, WaibelS, MeyerT, CroninS, McLaughlinRL, HardimanO, SappPC, TobinMD, WainLV, TomikB, SlowikA, LemmensR, RujescuD, SchulteC, GasserT, BrownRHJr., LandersJE, RobberechtW, LudolphAC, OphoffRA, VeldinkJH, van den BergLH. A large genome scan for rare CNVs in amyotrophic lateral sclerosis. Hum Mol Genet, 19:4091–4099. 2010.
48.
BogdanovM, BrownRH, MatsonW, SmartR, HaydenD, O'DonnellH, Flint BealM, CudkowiczM. Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med, 29:652–658. 2000.
49.
BoilleeS, Vande VeldeC, ClevelandDW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron, 52:39–59. 2006.
50.
BoilleeS, YamanakaK, LobsigerCS, CopelandNG, JenkinsNA, KassiotisG, KolliasG, ClevelandDW. Onset and progression in inherited ALS determined by motor neurons and microglia. Science, 312:1389–1392. 2006.
51.
BondLM, PedenAA, Kendrick-JonesJ, SellersJR, BussF. Myosin VI and its binding partner optineurin are involved in secretory vesicle fusion at the plasma membrane. Mol Biol Cell, 22:54–65. 2011.
52.
BoscoDA, LemayN, KoHK, ZhouH, BurkeC, KwiatkowskiTJJr., SappP, McKenna-YasekD, BrownRHJr., HaywardLJ. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum Mol Genet, 19:4160–4175. 2010.
53.
BoscoDA, MorfiniG, KarabacakNM, SongY, Gros-LouisF, PasinelliP, GoolsbyH, FontaineBA, LemayN, McKenna-YasekD, FroschMP, AgarJN, JulienJP, BradyST, BrownRHJr.Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci, 13:1396–1403. 2010.
54.
Boston-HowesW, GibbSL, WilliamsEO, PasinelliP, BrownRHJr., TrottiD. Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J Biol Chem, 281:14076–14084. 2006.
55.
BoucherieC, SchaferS, Lavand'hommeP, MaloteauxJM, HermansE. Chimerization of astroglial population in the lumbar spinal cord after mesenchymal stem cell transplantation prolongs survival in a rat model of amyotrophic lateral sclerosis. J Neurosci Res, 87:2034–2046. 2009.
56.
BowserR, LacomisD. Applying proteomics to the diagnosis and treatment of ALS and related diseases. Muscle Nerve, 40:753–762. 2009.
57.
BoyceM, BryantKF, JousseC, LongK, HardingHP, ScheunerD, KaufmanRJ, MaD, CoenDM, RonD, YuanJ. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science, 307:935–939. 2005.
58.
BraunRJ, SommerC, Carmona-GutierrezD, KhouryCM, RingJ, ButtnerS, MadeoF. Neurotoxic 43-kDa TAR DNA-binding protein (TDP-43) triggers mitochondrion-dependent programmed cell death in yeast. J Biol Chem, 286:19958–19972. 2011.
59.
BrettschneiderJ, MogelH, LehmensiekV, AhlertT, SussmuthS, LudolphAC, TumaniH. Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS)Neurochem Res, 33:2358–2363. 2008.
60.
BrockingtonA, WhartonSB, FernandoM, GelsthorpeCH, BaxterL, IncePG, LewisCE, ShawPJ. Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol, 65:26–36. 2006.
61.
BrooksBR. Risk factors in the early diagnosis of ALS: North American epidemiological studies. ALS CARE Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord, 1,Suppl 1:S19–S26. 2000.
62.
BuchanJR, ParkerR. Eukaryotic stress granules: the ins and outs of translation. Mol Cell, 36:932–941. 2009.
63.
BurattiE, BaralleFE. The molecular links between TDP-43 dysfunction and neurodegeneration. Adv Genet, 66:1–34. 2009.
64.
BurattiE, BaralleFE. The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol, 7:420–429. 2010.
65.
BurattiE, BrindisiA, GiombiM, TisminetzkyS, AyalaYM, BaralleFE. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem, 280:37572–37584. 2005.
66.
BurattiE, De ContiL, StuaniC, RomanoM, BaralleM, BaralleF. Nuclear factor TDP-43 can affect selected microRNA levels. Febs J, 277:2268–2281. 2010.
67.
BurnsCJ, BeardKK, CartmillJB. Mortality in chemical workers potentially exposed to 2,4-dichlorophenoxyacetic acid (2,4-D) 1945–94: an update. Occup Environ Med, 58:24–30. 2001.
68.
CaiH, LinX, XieC, LairdFM, LaiC, WenH, ChiangHC, ShimH, FarahMH, HokeA, PriceDL, WongPC. Loss of ALS2 function is insufficient to trigger motor neuron degeneration in knock-out mice but predisposes neurons to oxidative stress. J Neurosci, 25:7567–7574. 2005.
69.
CaiH, ShimH, LaiC, XieC, LinX, YangWJ, ChandranJ. ALS2/alsin knockout mice and motor neuron diseases. Neurodegener Dis, 5:359–366. 2008.
CarriMT. Minocycline for patients with ALS. Lancet Neurol, 7:118–119author reply 120–1212008.
72.
CarriMT, FerriA, CozzolinoM, CalabreseL, RotilioG. Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res Bull, 61:365–374. 2003.
CarterBJ, AnklesariaP, ChoiS, EngelhardtJF. Redox modifier genes and pathways in amyotrophic lateral sclerosis. Antioxid Redox Signal, 11:1569–1586. 2009.
75.
CasoniF, BassoM, MassignanT, GianazzaE, CheroniC, SalmonaM, BendottiC, BonettoV. Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis. J Biol Chem, 280:16295–16304. 2005.
76.
CassinaP, CassinaA, PeharM, CastellanosR, GandelmanM, de LeonA, RobinsonKM, MasonRP, BeckmanJS, BarbeitoL, RadiR. Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. J Neurosci, 28:4115–4122. 2008.
77.
ChaiA, WithersJ, KohYH, ParryK, BaoH, ZhangB, BudnikV, PennettaG. hVAPB, the causative gene of a heterogeneous group of motor neuron diseases in humans, is functionally interchangeable with its Drosophila homologue DVAP-33A at the neuromuscular junction. Hum Mol Genet, 17:266–280. 2008.
78.
ChandranJ, DingJ, CaiH. Alsin and the molecular pathways of amyotrophic lateral sclerosis. Mol Neurobiol, 36:224–231. 2007.
79.
ChangLY, SlotJW, GeuzeHJ, CrapoJD. Molecular immunocytochemistry of the CuZn superoxide dismutase in rat hepatocytes. J Cell Biol, 107:2169–2179. 1988.
80.
ChattopadhyayM, DurazoA, SohnSH, StrongCD, GrallaEB, WhiteleggeJP, ValentineJS. Initiation and elongation in fibrillation of ALS-linked superoxide dismutase. Proc Natl Acad Sci U S A, 105:18663–18668. 2008.
81.
ChattopadhyayM, ValentineJS. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid Redox Signal, 11:1603–1614. 2009.
82.
CheahBC, KiernanMC. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs, 13:911–920. 2010.
83.
CheahBC, VucicS, KrishnanAV, KiernanMC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem, 17:1942–1199. 2010.
ChenH, RichardM, SandlerDP, UmbachDM, KamelF. Head injury and amyotrophic lateral sclerosis. Am J Epidemiol, 166:810–816. 2007.
86.
ChenHJ, AnagnostouG, ChaiA, WithersJ, MorrisA, AdhikareeJ, PennettaG, de BellerocheJS. Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis. J Biol Chem, 285:40266–40281. 2010.
87.
ChenY, YangM, DengJ, ChenX, YeY, ZhuL, LiuJ, YeH, ShenY, LiY, RaoEJ, FushimiK, ZhouX, BigioEH, MesulamM, XuQ, WuJY. Expression of human FUS protein in Drosophila leads to progressive neurodegeneration. Protein Cell, 2:477–486. 2011.
88.
ChenYZ, BennettCL, HuynhHM, BlairIP, PulsI, IrobiJ, DierickI, AbelA, KennersonML, RabinBA, NicholsonGA, Auer-GrumbachM, WagnerK, De JongheP, GriffinJW, FischbeckKH, TimmermanV, CornblathDR, ChancePF. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4)Am J Hum Genet, 74:1128–1135. 2004.
89.
CheroniC, MarinoM, TortaroloM, VeglianeseP, De BiasiS, FontanaE, ZuccarelloLV, MaynardCJ, DantumaNP, BendottiC. Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis. Hum Mol Genet, 18:82–96. 2009.
90.
ChiaR, TattumMH, JonesS, CollingeJ, FisherEM, JacksonGS. Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis. PLoS One, 5:e10627. 2010.
91.
ChioA, BenziG, DossenaM, MutaniR, MoraG. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain, 128:472–476. 2005.
ChiuIM, PhatnaniH, KuligowskiM, TapiaJC, CarrascoMA, ZhangM, ManiatisT, CarrollMC. Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc Natl Acad Sci U S A, 106:20960–20965. 2009.
94.
ChowCY, LandersJE, BergrenSK, SappPC, GrantAE, JonesJM, EverettL, LenkGM, McKenna-YasekDM, WeismanLS, FiglewiczD, BrownRH, MeislerMH. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. Am J Hum Genet, 84:85–88. 2009.
95.
ChowCY, ZhangY, DowlingJJ, JinN, AdamskaM, ShigaK, SzigetiK, ShyME, LiJ, ZhangX, LupskiJR, WeismanLS, MeislerMH. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature, 448:68–72. 2007.
96.
CohenTJ, HwangAW, UngerT, TrojanowskiJQ, LeeVM. Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. Embo J, 31:1241–1252. 2011.
97.
ColombritaC, ZennaroE, FalliniC, WeberM, SommacalA, BurattiE, SilaniV, RattiA. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem, 111:1051–1061. 2009.
98.
ConfortiFL, SprovieriT, MazzeiR, UngaroC, La BellaV, TessitoreA, PatitucciA, MagarielloA, GabrieleAL, TedeschiG, SimoneIL, MajoranaG, ValentinoP, CondinoF, BonoF, MonsurroMR, MugliaM, QuattroneA. A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy. Neuromuscul Disord, 18:68–70. 2008.
99.
ConfortiFL, SprovieriT, MazzeiR, UngaroC, TessitoreA, TedeschiG, PatitucciA, MagarielloA, GabrieleA, LabellaV, SimoneIL, MajoranaG, MonsurroMR, ValentinoP, MugliaM, QuattroneA. Sporadic ALS is not associated with VAPB gene mutations in Southern Italy. J Negat Results Biomed, 5:7. 2006.
100.
CortiS, LocatelliF, DonadoniC, GuglieriM, PapadimitriouD, StrazzerS, Del BoR, ComiGP. Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain, 127:2518–2532. 2004.
101.
CortiS, LocatelliF, PapadimitriouD, Del BoR, NizzardoM, NardiniM, DonadoniC, SalaniS, FortunatoF, StrazzerS, BresolinN, ComiGP. Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model. Brain, 130:1289–1305. 2007.
102.
CortiS, NizzardoM, NardiniM, DonadoniC, SalaniS, SimoneC, FalconeM, RiboldiG, GovoniA, BresolinN, ComiGP. Systemic transplantation of c-kit+ cells exerts a therapeutic effect in a model of amyotrophic lateral sclerosis. Hum Mol Genet, 19:3782–3796. 2010.
103.
CouthouisJ, HartMP, ShorterJ, DeJesus-HernandezM, ErionR, OristanoR, LiuAX, RamosD, JethavaN, HosangadiD, EpsteinJ, ChiangA, DiazZ, NakayaT, IbrahimF, KimHJ, SolskiJA, WilliamsKL, Mojsilovic-PetrovicJ, IngreC, BoylanK, Graff-RadfordNR, DicksonDW, Clay-FalconeD, ElmanL, McCluskeyL, GreeneR, KalbRG, LeeVM, TrojanowskiJQ, LudolphA, RobberechtW, AndersenPM, NicholsonGA, BlairIP, KingOD, BoniniNM, Van DeerlinV, RademakersR, MourelatosZ, GitlerAD. A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A, 108:20881–20890. 2011.
CoxPA, SacksOW. Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. Neurology, 58:956–959. 2002.
106.
CozzolinoM, CarriMT. Mitochondrial dysfunction in ALS. Prog Neurobiol, 1802:45–51. 2011.
107.
CozzolinoM, FerriA, CarriMT. Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. Antioxid Redox Signal, 10:405–443. 2008.
108.
CozzolinoM, PesaresiMG, AmoriI, CrosioC, FerriA, NenciniM, CarriMT. Oligomerization of mutant SOD1 in mitochondria of motoneuronal cells drives mitochondrial damage and cell toxicity. Antioxid Redox Signal, 11:1547–1558. 2009.
109.
CrapoJD, OuryT, RabouilleC, SlotJW, ChangLY. Copper,zinc superoxide dismutase is primarily a cytosolic protein in human cells. Proc Natl Acad Sci U S A, 89:10405–10409. 1992.
110.
CrippaV, SauD, RusminiP, BoncoraglioA, OnestoE, BolzoniE, GalbiatiM, FontanaE, MarinoM, CarraS, BendottiC, De BiasiS, PolettiA. The small heat shock protein B8 (HspB8) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS)Hum Mol Genet, 19:3440–3456. 2010.
111.
CroninS, BergerS, DingJ, SchymickJC, WasheckaN, HernandezDG, GreenwayMJ, BradleyDG, TraynorBJ, HardimanO. A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum Mol Genet, 17:768–774. 2008.
112.
CrozatA, AmanP, MandahlN, RonD. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature, 363:640–644. 1993.
113.
CudkowiczM, BozikME, IngersollEW, MillerR, MitsumotoH, ShefnerJ, MooreDH, SchoenfeldD, MatherJL, ArchibaldD, SullivanM, AmburgeyC, MoritzJ, GribkoffVK. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med, 17:1652–1656. 2011.
114.
CudkowiczME, AndresPL, MacdonaldSA, BedlackRS, ChoudryR, BrownRHJr., ZhangH, SchoenfeldDA, ShefnerJ, MatsonS, MatsonWR, FerranteRJ. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler, 10:99–106. 2009.
Da CruzS, ClevelandDW. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr Opin Neurobiol, 21:904–919. 2011.
117.
Dadon-NachumM, MelamedE, OffenD. The “dying-back” phenomenon of motor neurons in ALS. J Mol Neurosci, 43:470–477. 2011.
118.
Dal CantoMC, GurneyME. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol, 145:1271–1279. 1994.
119.
DamianoM, StarkovAA, PetriS, KipianiK, KiaeiM, MattiazziM, Flint BealM, ManfrediG. Neural mitochondrial Ca2+ capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice. J Neurochem, 96:1349–1361. 2006.
De AmicisA, PianeM, FerrariF, FanciulliM, DeliaD, ChessaL. Role of senataxin in DNA damage and telomeric stability. DNA Repair (Amst), 10:199–209. 2011.
122.
de CarvalhoM, SwashM. Amyotrophic lateral sclerosis: an update. Curr Opin Neurol, 24:497–503. 2011.
123.
De StefaniD, BononiA, RomagnoliA, MessinaA, De PintoV, PintonP, RizzutoR. VDAC1 selectively transfers apoptotic Ca(2+) signals to mitochondria. Cell Death Differ, 19:267–273. 2012.
124.
De VosKJ, ChapmanAL, TennantME, ManserC, TudorEL, LauKF, BrownleesJ, AckerleyS, ShawPJ, McLoughlinDM, ShawCE, LeighPN, MillerCC, GriersonAJ. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum Mol Genet, 16:2720–2728. 2007.
125.
DeasE, WoodNW, Plun-FavreauH. Mitophagy and Parkinson's disease: the PINK1-parkin link. Biochim Biophys Acta, 1813:623–633. 2011.
Del BoR, TilocaC, PensatoV, CorradoL, RattiA, TicozziN, CortiS, CastellottiB, MazziniL, SoraruG, CeredaC, D'AlfonsoS, GelleraC, ComiGP, SilaniV. Novel optineurin mutations in patients with familial and sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry, 82:1239–1243. 2011.
128.
DengHX, BigioEH, ZhaiH, FectoF, AjroudK, ShiY, YanJ, MishraM, Ajroud-DrissS, HellerS, SufitR, SiddiqueN, MugnainiE, SiddiqueT. Differential Involvement of Optineurin in Amyotrophic Lateral Sclerosis With or Without SOD1 Mutations. Arch Neurol, 68:1057–1061. 2011.
129.
DengHX, ChenW, HongST, BoycottKM, GorrieGH, SiddiqueN, YangY, FectoF, ShiY, ZhaiH, JiangH, HiranoM, RampersaudE, JansenGH, DonkervoortS, BigioEH, BrooksBR, AjroudK, SufitRL, HainesJL, MugnainiE, Pericak-VanceMA, SiddiqueT. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature, 477:211–215. 2011.
130.
DengHX, JiangH, FuR, ZhaiH, ShiY, LiuE, HiranoM, Dal CantoMC, SiddiqueT. Molecular dissection of ALS-associated toxicity of SOD1 in transgenic mice using an exon-fusion approach. Hum Mol Genet, 17:2310–2319. 2008.
131.
DengHX, ShiY, FurukawaY, ZhaiH, FuR, LiuE, GorrieGH, KhanMS, HungWY, BigioEH, LukasT, Dal CantoMC, O'HalloranTV, SiddiqueT. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc Natl Acad Sci U S A, 103:7142–7147. 2006.
132.
DengHX, ZhaiH, FuR, ShiY, GorrieGH, YangY, LiuE, Dal CantoMC, MugnainiE, SiddiqueT. Distal axonopathy in an alsin-deficient mouse model. Hum Mol Genet, 16:2911–2920. 2007.
133.
DevonRS, OrbanPC, GerrowK, BarbieriMA, SchwabC, CaoLP, HelmJR, BissadaN, Cruz-AguadoR, DavidsonTL, WitmerJ, MetzlerM, LamCK, TetzlaffW, SimpsonEM, McCafferyJM, El-HusseiniAE, LeavittBR, HaydenMR. Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. Proc Natl Acad Sci U S A, 103:9595–9600. 2006.
134.
DeweyCM, CenikB, SephtonCF, DriesDR, MayerP3rd, GoodSK, JohnsonBA, HerzJ, YuG. TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. Mol Cell Biol, 31:1098–1108. 2011.
135.
Di GiorgioFP, CarrascoMA, SiaoMC, ManiatisT, EgganK. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci, 10:608–614. 2007.
136.
Di PotoC, IadarolaP, BardoniAM, PassadoreI, GiorgettiS, CeredaC, CarriMT, CeroniM, SalviniR. 2-DE and MALDI-TOF-MS for a comparative analysis of proteins expressed in different cellular models of amyotrophic lateral sclerosis. Electrophoresis, 28:4320–4329. 2007.
137.
DimosJT, RodolfaKT, NiakanKK, WeisenthalLM, MitsumotoH, ChungW, CroftGF, SaphierG, LeibelR, GolandR, WichterleH, HendersonCE, EgganK. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science, 321:1218–1221. 2008.
138.
DobrowolnyG, AucelloM, RizzutoE, BeccaficoS, MammucariC, BoncompagniS, BeliaS, WannenesF, NicolettiC, Del PreteZ, RosenthalN, MolinaroM, ProtasiF, FanoG, SandriM, MusaroA. Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab, 8:425–436. 2008.
139.
DobrowolnyG, GiacintiC, PelosiL, NicolettiC, WinnN, BarberiL, MolinaroM, RosenthalN, MusaroA. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol, 168:193–199. 2005.
DuanW, LiX, ShiJ, GuoY, LiZ, LiC. Mutant TAR DNA-binding protein-43 induces oxidative injury in motor neuron-like cell. Neuroscience, 169:1621–1629. 2010.
142.
DuexJE, NauJJ, KauffmanEJ, WeismanLS. Phosphoinositide 5-phosphatase Fig 4p is required for both acute rise and subsequent fall in stress-induced phosphatidylinositol 3,5-bisphosphate levels. Eukaryot Cell, 5:723–731. 2006.
143.
DuexJE, TangF, WeismanLS. The Vac14p-Fig4p complex acts independently of Vac7p and couples PI3,5P2 synthesis and turnover. J Cell Biol, 172:693–704. 2006.
Eymard-PierreE, LescaG, DolletS, SantorelliFM, di CapuaM, BertiniE, Boespflug-TanguyO. Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene. Am J Hum Genet, 71:518–527. 2002.
153.
Eymard-PierreE, YamanakaK, HaeusslerM, KressW, Gauthier-BarichardF, CombesP, ClevelandDW, Boespflug-TanguyO. Novel missense mutation in ALS2 gene results in infantile ascending hereditary spastic paralysis. Ann Neurol, 59:976–980. 2006.
154.
EzziSA, LariviereR, UrushitaniM, JulienJP. Neuronal over-expression of chromogranin A accelerates disease onset in a mouse model of ALS. J Neurochem, 115:1102–1111. 2010.
155.
EzziSA, UrushitaniM, JulienJP. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem, 102:170–178. 2007.
156.
FaberPW, BarnesGT, SrinidhiJ, ChenJ, GusellaJF, MacDonaldME. Huntingtin interacts with a family of WW domain proteins. Hum Mol Genet, 7:1463–1474. 1998.
157.
FedericiT, BoulisNM. Gene therapy for amyotrophic lateral sclerosis. Neurobiol Dis, 2011[Epub ahead of print]DOI:dx.doi.org/10.1016/j.nbd.2011.08.018
158.
FedericiT, TaubJS, BaumGR, GraySJ, GriegerJC, MatthewsKA, HandyCR, PassiniMA, SamulskiRJ, BoulisNM. Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther, 2011[Epub ahead of print]DOI:10.1038/gt.2011.130.
159.
FeiguinF, GodenaVK, RomanoG, D'AmbrogioA, KlimaR, BaralleFE. Depletion of TDP-43 affects Drosophila motoneurons terminal synapsis and locomotive behavior. FEBS Lett, 583:1586–1592. 2009.
160.
FengHL, LengY, MaCH, ZhangJ, RenM, ChuangDM. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience, 155:567–572. 2008.
161.
FergusonCJ, LenkGM, MeislerMH. Defective autophagy in neurons and astrocytes from mice deficient in PI(3,5)P2. Hum Mol Genet, 18:4868–4878. 2009.
162.
Fernandez-SantiagoR, HoenigS, LichtnerP, SperfeldAD, SharmaM, BergD, WeichenriederO, IlligT, EgerK, MeyerT, AnneserJ, MunchC, ZierzS, GasserT, LudolphA. Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis. J Neurol, 256:1337–1342. 2009.
163.
FerraiuoloL, HeathPR, HoldenH, KasherP, KirbyJ, ShawPJ. Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. J Neurosci, 27:9201–9219. 2007.
164.
FerriA, CozzolinoM, CrosioC, NenciniM, CasciatiA, GrallaEB, RotilioG, ValentineJS, CarriMT. Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials. Proc Natl Acad Sci U S A, 103:13860–13865. 2006.
165.
FerriA, FiorenzoP, NenciniM, CozzolinoM, PesaresiMG, ValleC, SepeS, MorenoS, CarriMT. Glutaredoxin 2 prevents aggregation of mutant SOD1 in mitochondria and abolishes its toxicity. Hum Mol Genet, 19:4529–4542. 2010.
166.
FerriA, NenciniM, CasciatiA, CozzolinoM, AngeliniDF, LongoneP, SpalloniA, RotilioG, CarriMT. Cell death in amyotrophic lateral sclerosis: interplay between neuronal and glial cells. Faseb J, 18:1261–1263. 2004.
167.
FerrucciM, FulceriF, TotiL, SoldaniP, SicilianoG, PaparelliA, FornaiF. Protein clearing pathways in ALS. Arch Ital Biol, 149:121–149. 2011.
168.
FieldLS, FurukawaY, O'HalloranTV, CulottaVC. Factors controlling the uptake of yeast copper/zinc superoxide dismutase into mitochondria. J Biol Chem, 278:28052–28059. 2003.
169.
FieselFC, VoigtA, WeberSS, Van den HauteC, WaldenmaierA, GornerK, WalterM, AndersonML, KernJV, RasseTM, SchmidtT, SpringerW, KirchnerR, BoninM, NeumannM, BaekelandtV, Alunni-FabbroniM, SchulzJB, KahlePJ. Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. Embo J, 29:209–221. 2010.
170.
FinkelsteinA, KunisG, SeksenyanA, RonenA, BerkutzkiT, AzoulayD, Koronyo-HamaouiM, SchwartzM. Abnormal changes in NKT cells, the IGF-1 axis, and liver pathology in an animal model of ALS. PLoS One, 6:e22374. 2011.
171.
FischerLR, GlassJD. Axonal degeneration in motor neuron disease. Neurodegener Dis, 4:431–442. 2007.
172.
FischerLR, IgoudjilA, MagraneJ, LiY, HansenJM, ManfrediG, GlassJD. SOD1 targeted to the mitochondrial intermembrane space prevents motor neuropathy in the Sod1 knockout mouse. Brain, 134:196–209. 2011.
173.
FitzmauricePS, ShawIC, KleinerHE, MillerRT, MonksTJ, LauSS, MitchellJD, LynchPG. Evidence for DNA damage in amyotrophic lateral sclerosis. Muscle Nerve, 19:797–798. 1996.
174.
ForanE, BogushA, GoffredoM, RoncagliaP, GustincichS, PasinelliP, TrottiD. Motor neuron impairment mediated by a sumoylated fragment of the glial glutamate transporter EAAT2. Glia, 59:1719–1731. 2011.
175.
ForanE, TrottiD. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid Redox Signal, 11:1587–1602. 2009.
176.
FornaiF, LongoneP, CafaroL, KastsiuchenkaO, FerrucciM, MancaML, LazzeriG, SpalloniA, BellioN, LenziP, ModugnoN, SicilianoG, IsidoroC, MurriL, RuggieriS, PaparelliA. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A, 105:2052–2057. 2008.
177.
FranzCK, FedericiT, YangJ, BackusC, OhSS, TengQ, CarltonE, BishopKM, GasmiM, BartusRT, FeldmanEL, BoulisNM. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol Dis, 33:473–481. 2009.
178.
FreibaumBD, ChittaRK, HighAA, TaylorJP. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res, 9:1104–1120. 2010.
179.
FujiiR, OkabeS, UrushidoT, InoueK, YoshimuraA, TachibanaT, NishikawaT, HicksGG, TakumiT. The RNA binding protein TLS is translocated to dendritic spines by mGluR5 activation and regulates spine morphology. Curr Biol, 15:587–593. 2005.
180.
FujiiR, TakumiT. TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines. J Cell Sci, 118:5755–5765. 2005.
181.
FujitaY, MizunoY, TakatamaM, OkamotoK. Anterior horn cells with abnormal TDP-43 immunoreactivities show fragmentation of the Golgi apparatus in ALS. J Neurol Sci, 269:30–34. 2008.
182.
FujitaY, OkamotoK. Golgi apparatus of the motor neurons in patients with amyotrophic lateral sclerosis and in mice models of amyotrophic lateral sclerosis. Neuropathology, 25:388–394. 2005.
183.
FukushimaM, LeeSM, MoroN, HovdaDA, SuttonRL. Metabolic and histologic effects of sodium pyruvate treatment in the rat after cortical contusion injury. J Neurotrauma, 26:1095–1110. 2009.
184.
FurukawaY, O'HalloranTV. Posttranslational modifications in Cu,Zn-superoxide dismutase and mutations associated with amyotrophic lateral sclerosis. Antioxid Redox Signal, 8:847–867. 2006.
185.
GalJ, StromAL, KiltyR, ZhangF, ZhuH. p62 accumulates and enhances aggregate formation in model systems of familial amyotrophic lateral sclerosis. J Biol Chem, 282:11068–11077. 2007.
186.
GalJ, ZhangJ, KwinterDM, ZhaiJ, JiaH, JiaJ, ZhuH. Nuclear localization sequence of FUS and induction of stress granules by ALS mutants. Neurobiol Aging, 32:2323.e27–2323.e40. 2010.
Garbuzova-DavisS, HallerE, SaportaS, KolomeyI, NicosiaSV, SanbergPR. Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res, 1157:126–137. 2007.
189.
Garbuzova-DavisS, SaportaS, HallerE, KolomeyI, BennettSP, PotterH, SanbergPR. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS One, 2:e1205. 2007.
190.
GardinerM, TothR, VandermoereF, MorriceNA, RouseJ. Identification and characterization of FUS/TLS as a new target of ATM. Biochem J, 415:297–307. 2008.
191.
GelleraC, ColombritaC, TicozziN, CastellottiB, BragatoC, RattiA, TaroniF, SilaniV. Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis. Neurogenetics, 9:33–40. 2008.
192.
GertzB, WongM, MartinLJ. Nuclear Localization of Human SOD1 and Mutant SOD1-Specific Disruption of Survival Motor Neuron Protein Complex in Transgenic Amyotrophic Lateral Sclerosis Mice. J Neuropathol Exp Neurol, 71:162–177. 2012.
193.
GertzM, SteegbornC. The Lifespan-regulator p66Shc in mitochondria: redox enzyme or redox sensor?Antioxid Redox Signal, 13:1417–1428. 2010.
194.
GeserF, O'DwyerL, HardimanO, BedeP, BokdeAL, PrvulovicD, TrojanowskiJQ, HampelHJ. On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Prog Neurobiol, 95:649–662. 2011.
195.
GibbSL, Boston-HowesW, LavinaZS, GustincichS, BrownRHJr., PasinelliP, TrottiD. A caspase-3-cleaved fragment of the glial glutamate transporter EAAT2 is sumoylated and targeted to promyelocytic leukemia nuclear bodies in mutant SOD1-linked amyotrophic lateral sclerosis. J Biol Chem, 282:32480–32490. 2007.
196.
GillA, KiddJ, VieiraF, ThompsonK, PerrinS. No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS. PLoS One, 4:e6489. 2009.
197.
Gimenez y RibottaM, RevahF, PradierL, LoquetI, MalletJ, PrivatA. Prevention of motoneuron death by adenovirus-mediated neurotrophic factors. J Neurosci Res, 48:281–285. 1997.
198.
GitchoMA, BalohRH, ChakravertyS, MayoK, NortonJB, LevitchD, HatanpaaKJ, WhiteCL3rd, BigioEH, CaselliR, BakerM, Al-LoziMT, MorrisJC, PestronkA, RademakersR, GoateAM, CairnsNJ. TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol, 63:535–538. 2008.
199.
GkogkasC, MiddletonS, KremerAM, WardropeC, HannahM, GillingwaterTH, SkehelP. VAPB interacts with and modulates the activity of ATF6. Hum Mol Genet, 17:1517–1526. 2008.
GolombBA, KwonEK, KoperskiS, EvansMA. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf, 32:649–661. 2009.
202.
Gonzalez de AguilarJL, Niederhauser-WiederkehrC, HalterB, De TapiaM, Di ScalaF, DemouginP, DupuisL, PrimigM, MeiningerV, LoefflerJP. Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis mouse model. Physiol Genomics, 32:207–218. 2008.
GordonPH, MooreDH, MillerRG, FlorenceJM, VerheijdeJL, DoorishC, HiltonJF, SpitalnyGM, MacArthurRB, MitsumotoH, NevilleHE, BoylanK, MozaffarT, BelshJM, RavitsJ, BedlackRS, GravesMC, McCluskeyLF, BarohnRJ, TandanR. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol, 6:1045–1053. 2007.
205.
GouldTW, BussRR, VinsantS, PrevetteD, SunW, KnudsonCM, MilliganCE, OppenheimRW. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J Neurosci, 26:8774–8786. 2006.
206.
GowingG, SvendsenCN. Stem cell transplantation for motor neuron disease: current approaches and future perspectives. Neurotherapeutics, 8:591–606. 2011.
207.
GraySJ, MatagneV, BachaboinaL, YadavS, OjedaSR, SamulskiRJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther, 19:1058–1069. 2011.
208.
GreenwayMJ, AlexanderMD, EnnisS, TraynorBJ, CorrB, FrostE, GreenA, HardimanO. A novel candidate region for ALS on chromosome 14q11.2. Neurology, 63:1936–1938. 2004.
209.
GreenwayMJ, AndersenPM, RussC, EnnisS, CashmanS, DonaghyC, PattersonV, SwinglerR, KieranD, PrehnJ, MorrisonKE, GreenA, AcharyaKR, BrownRHJr., HardimanO. ANG mutations segregate with familial and “sporadic” amyotrophic lateral sclerosis. Nat Genet, 38:411–413. 2006.
210.
GregoryRI, YanKP, AmuthanG, ChendrimadaT, DoratotajB, CoochN, ShiekhattarR. The Microprocessor complex mediates the genesis of microRNAs. Nature, 432:235–240. 2004.
211.
Gros-LouisF, SoucyG, LariviereR, JulienJP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem, 113:1188–1199. 2010.
212.
GrossDP, BurgardCA, ReddehaseS, LeitchJM, CulottaVC, HellK. Mitochondrial Ccs1 contains a structural disulfide bond crucial for the import of this unconventional substrate by the disulfide relay system. Mol Biol Cell, 22:3758–3767. 2011.
213.
GrosskreutzJ, HaastertK, DewilM, Van DammeP, CallewaertG, RobberechtW, DenglerR, Van Den BoschL. Role of mitochondria in kainate-induced fast Ca2+ transients in cultured spinal motor neurons. Cell Calcium, 42:59–69. 2007.
214.
GrosskreutzJ, Van Den BoschL, KellerBU. Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium, 47:165–174. 2010.
215.
GruzmanA, WoodWL, AlpertE, PrasadMD, MillerRG, RothsteinJD, BowserR, HamiltonR, WoodTD, ClevelandDW, LingappaVR, LiuJ. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A, 104:12524–12529. 2007.
216.
GuoW, ChenY, ZhouX, KarA, RayP, ChenX, RaoEJ, YangM, YeH, ZhuL, LiuJ, XuM, YangY, WangC, ZhangD, BigioEH, MesulamM, ShenY, XuQ, FushimiK, WuJY. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat Struct Mol Biol, 18:822–830. 2011.
217.
GurneyME, CuttingFB, ZhaiP, DobleA, TaylorCP, AndrusPK, HallED. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol, 39:147–157. 1996.
218.
HaapasaloA, ViswanathanJ, BertramL, SoininenH, TanziRE, HiltunenM. Emerging role of Alzheimer's disease-associated ubiquilin-1 in protein aggregation. Biochem Soc Trans, 38:150–155. 2010.
HadanoS, HandCK, OsugaH, YanagisawaY, OtomoA, DevonRS, MiyamotoN, Showguchi-MiyataJ, OkadaY, SingarajaR, FiglewiczDA, KwiatkowskiT, HoslerBA, SagieT, SkaugJ, NasirJ, BrownRHJr., SchererSW, RouleauGA, HaydenMR, IkedaJE. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet, 29:166–173. 2001.
221.
HallierM, LergaA, BarnacheS, TavitianA, Moreau-GachelinF. The transcription factor Spi-1/PU.1 interacts with the potential splicing factor TLS. J Biol Chem, 273:4838–4842. 1998.
222.
HalterB, Gonzalez de AguilarJL, ReneF, PetriS, FrickerB, Echaniz-LagunaA, DupuisL, LarmetY, LoefflerJP. Oxidative stress in skeletal muscle stimulates early expression of Rad in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med, 48:915–923. 2010.
223.
HandCK, KhorisJ, SalachasF, Gros-LouisF, LopesAA, Mayeux-PortasV, BrewerCG, BrownRHJr., MeiningerV, CamuW, RouleauGA. A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am J Hum Genet, 70:251–256. 2002.
224.
HansonKA, KimSH, WassarmanDA, TibbettsRS. Ubiquilin modifies TDP-43 toxicity in a Drosophila model of amyotrophic lateral sclerosis (ALS)J Biol Chem, 285:11068–11072. 2010.
225.
HarrazMM, MardenJJ, ZhouW, ZhangY, WilliamsA, SharovVS, NelsonK, LuoM, PaulsonH, SchoneichC, EngelhardtJF. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J Clin Invest, 118:659–670. 2008.
226.
HarwoodCA, McDermottCJ, ShawPJ. Physical activity as an exogenous risk factor in motor neuron disease (MND): a review of the evidence. Amyotroph Lateral Scler, 10:191–204. 2009.
227.
HattulaK, PeranenJ. FIP-2, a coiled-coil protein, links Huntingtin to Rab8 and modulates cellular morphogenesis. Curr Biol, 10:1603–1606. 2000.
228.
HechtMJ, FellnerC, SchmidA, NeundorferB, FellnerFA. Cortical T2 signal shortening in amyotrophic lateral sclerosis is not due to iron deposits. Neuroradiology, 47:805–808. 2005.
HenkelJS, BeersDR, WenS, BowserR, AppelSH. Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology, 72:1614–1616. 2009.
231.
HenriquesA, PitzerC, SchneiderA. Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?Front Neurosci, 4:32. 2010.
232.
HensleyK, MhatreM, MouS, PyeQN, StewartC, WestM, WilliamsonKS. On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal, 8:2075–2087. 2006.
233.
HentatiA, BejaouiK, Pericak-VanceMA, HentatiF, SpeerMC, HungWY, FiglewiczDA, HainesJ, RimmlerJ, Ben HamidaCet al.Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. Nat Genet, 7:425–428. 1994.
234.
HentatiA, OuahchiK, Pericak-VanceMA, NijhawanD, AhmadA, YangY, RimmlerJ, HungW, SchlotterB, AhmedA, Ben HamidaM, HentatiF, SiddiqueT. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics, 2:55–60. 1998.
235.
HesterME, MurthaMJ, SongS, RaoM, MirandaCJ, MeyerK, TianJ, BoultingG, SchafferDV, ZhuMX, PfaffSL, GageFH, KasparBK. Rapid and Efficient Generation of Functional Motor Neurons From Human Pluripotent Stem Cells Using Gene Delivered Transcription Factor Codes. Mol Ther, 19:1905–1912. 2011.
236.
HetzC, ThielenP, MatusS, NassifM, CourtF, KiffinR, MartinezG, CuervoAM, BrownRH, GlimcherLH. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev, 23:2294–2306. 2009.
237.
HeurichB, El IdrissiNB, DonevRM, PetriS, ClausP, NealJ, MorganBP, RamagliaV. Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. J Neuroimmunol, 235:104–109. 2011.
238.
HicksGG, SinghN, NashabiA, MaiS, BozekG, KlewesL, ArapovicD, WhiteEK, KouryMJ, OltzEM, Van KaerL, RuleyHE. Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat Genet, 24:175–179. 2000.
239.
HigginsCM, JungC, DingH, XuZ. Mutant Cu, Zn superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J Neurosci, 22:RC215. 2002.
240.
HoellJI, LarssonE, RungeS, NusbaumJD, DuggimpudiS, FaraziTA, HafnerM, BorkhardtA, SanderC, TuschlT. RNA targets of wild-type and mutant FET family proteins. Nat Struct Mol Biol, 18:1428–1431. 2011.
241.
HortobagyiT, TroakesC, NishimuraAL, VanceC, van SwietenJC, SeelaarH, KingA, Al-SarrajS, RogeljB, ShawCE. Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders. Acta Neuropathol, 121:519–527. 2011.
242.
HossainiM, CanoSC, van DisV, HaasdijkED, HoogenraadCC, HolstegeJC, JaarsmaD. Spinal inhibitory interneuron pathology follows motor neuron degeneration independent of glial mutant superoxide dismutase 1 expression in SOD1-ALS mice. J Neuropathol Exp Neurol, 70:662–677. 2011.
243.
HuangC, ZhouH, TongJ, ChenH, LiuYJ, WangD, WeiX, XiaXG. FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PLoS Genet, 7:e1002011. 2011.
HwangDH, LeeHJ, ParkIH, SeokJI, KimBG, JooIS, KimSU. Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther, 16:1234–1244. 2009.
246.
IgazLM, KwongLK, LeeEB, Chen-PlotkinA, SwansonE, UngerT, MalundaJ, XuY, WintonMJ, TrojanowskiJQ, LeeVM. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest, 121:726–738. 2011.
247.
IgoudjilA, MagraneJ, FischerLR, KimHJ, HerviasI, DumontM, CortezC, GlassJD, StarkovAA, ManfrediG. In vivo pathogenic role of mutant SOD1 localized in the mitochondrial intermembrane space. J Neurosci, 31:15826–15837. 2011.
248.
IguchiY, KatsunoM, TakagiS, IshigakiS, NiwaJI, HasegawaM, TanakaF, SobueG. Oxidative stress induced by glutathione depletion reproduces pathological modifications of TDP-43 linked to TDP-43 proteinopathies. Neurobiol Dis, 45:862–870. 2011.
249.
IkoY, KodamaTS, KasaiN, OyamaT, MoritaEH, MutoT, OkumuraM, FujiiR, TakumiT, TateS, MorikawaK. Domain architectures and characterization of an RNA-binding protein, TLS. J Biol Chem, 279:44834–44840. 2004.
IlievaH, PolymenidouM, ClevelandDW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol, 187:761–772. 2009.
252.
InoueE, TanoK, YoshiiH, NakamuraJ, TadaS, WatanabeM, SekiM, EnomotoT. SOD1 Is Essential for the Viability of DT40 Cells and Nuclear SOD1 Functions as a Guardian of Genomic DNA. J Nucleic Acids, 2010Article ID 7959462010.
253.
IshigakiS, NiwaJ, YamadaS, TakahashiM, ItoT, SoneJ, DoyuM, UranoF, SobueG. Dorfin-CHIP chimeric proteins potently ubiquitylate and degrade familial ALS-related mutant SOD1 proteins and reduce their cellular toxicity. Neurobiol Dis, 25:331–341. 2007.
254.
IsraelsonA, ArbelN, Da CruzS, IlievaH, YamanakaK, Shoshan-BarmatzV, ClevelandDW. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron, 67:575–587. 2010.
255.
ItoH, FujitaK, NakamuraM, WateR, KanekoS, SasakiS, YamaneK, SuzukiN, AokiM, ShibataN, TogashiS, KawataA, MochizukiY, MizutaniT, MaruyamaH, HiranoA, TakahashiR, KawakamiH, KusakaH. Optineurin is co-localized with FUS in basophilic inclusions of ALS with FUS mutation and in basophilic inclusion body disease. Acta Neuropathol, 121:555–557. 2011.
JaarsmaD, RognoniF, van DuijnW, VerspagetHW, HaasdijkED, HolstegeJC. CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta Neuropathol (Berl), 102:293–305. 2001.
258.
JaarsmaD, TeulingE, HaasdijkED, De ZeeuwCI, HoogenraadCC. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J Neurosci, 28:2075–2088. 2008.
259.
JacquierA, BellouzeS, BlanchardS, BohlD, HaaseG. Astrocytic protection of spinal motor neurons but not cortical neurons against loss of Als2/alsin function. Hum Mol Genet, 18:2127–2139. 2009.
260.
JaiswalMK, KellerBU. Cu/Zn superoxide dismutase typical for familial amyotrophic lateral sclerosis increases the vulnerability of mitochondria and perturbs Ca2+ homeostasis in SOD1G93A mice. Mol Pharmacol, 75:478–489. 2009.
261.
JaiswalMK, ZechWD, GoosM, LeutbecherC, FerriA, ZippeliusA, CarriMT, NauR, KellerBU. Impairment of mitochondrial calcium handling in a mtSOD1 cell culture model of motoneuron disease. BMC Neurosci, 10:64. 2009.
JeongSY, RathoreKI, SchulzK, PonkaP, ArosioP, DavidS. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci, 29:610–619. 2009.
264.
JohnsonBS, SneadD, LeeJJ, McCafferyJM, ShorterJ, GitlerAD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem, 284:20329–20339. 2009.
JoycePI, FrattaP, FisherEM, Acevedo-ArozenaA. SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm Genome, 22:420–448. 2011.
267.
JuJS, WeihlCC. Inclusion body myopathy, Paget's disease of the bone and fronto-temporal dementia: a disorder of autophagy. Hum Mol Genet, 19:R38–R45. 2010.
268.
JulienJP. ALS: astrocytes move in as deadly neighbors. Nat Neurosci, 10:535–537. 2007.
269.
JustN, MoreauC, LassalleP, GossetP, PerezT, Brunaud-DanelV, WallaertB, DesteeA, DefebvreL, TonnelAB, DevosD. High erythropoietin and low vascular endothelial growth factor levels in cerebrospinal fluid from hypoxemic ALS patients suggest an abnormal response to hypoxia. Neuromuscul Disord, 17:169–173. 2007.
270.
KabashiE, BercierV, LissoubaA, LiaoM, BrusteinE, RouleauGA, DrapeauP. FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoS Genet, 7:e1002214. 2011.
271.
KabashiE, LinL, TradewellML, DionPA, BercierV, BourgouinP, RochefortD, Bel HadjS, DurhamHD, Vande VeldeC, RouleauGA, DrapeauP. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet, 19:671–683. 2010.
KabutaT, SuzukiY, WadaK. Degradation of amyotrophic lateral sclerosis-linked mutant Cu,Zn-superoxide dismutase proteins by macroautophagy and the proteasome. J Biol Chem, 281:30524–30533. 2006.
274.
KalraS, GengeA, ArnoldDL. A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotroph Lateral Scler Other Motor Neuron Disord, 4:22–26. 2003.
275.
KamelF, UmbachDM, HuH, MunsatTL, ShefnerJM, TaylorJA, SandlerDP. Lead exposure as a risk factor for amyotrophic lateral sclerosis. Neurodegener Dis, 2:195–201. 2005.
276.
KanaiY, DohmaeN, HirokawaN. Kinesin transports RNA: isolation and characterization of an RNA-transporting granule. Neuron, 43:513–525. 2004.
277.
KanekuraK, SuzukiH, AisoS, MatsuokaM. ER stress and unfolded protein response in amyotrophic lateral sclerosis. Mol Neurobiol, 39:81–89. 2009.
278.
KarchCM, PrudencioM, WinklerDD, HartPJ, BorcheltDR. Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS. Proc Natl Acad Sci U S A, 106:7774–7779. 2009.
279.
KasarskisEJ, LindquistJH, CoffmanCJ, GrambowSC, FeussnerJR, AllenKD, OddoneEZ, KaminsKA, HornerRD. Clinical aspects of ALS in Gulf War veterans. Amyotroph Lateral Scler, 10:35–41. 2009.
280.
KasarskisEJ, TandonL, LovellMA, EhmannWD. Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. J Neurol Sci, 130:203–208. 1995.
281.
KasparBK, LladoJ, SherkatN, RothsteinJD, GageFH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science, 301:839–842. 2003.
282.
KawamataH, MagraneJ, KunstC, KingMP, ManfrediG. Lysyl-tRNA synthetase is a target for mutant SOD1 toxicity in mitochondria. J Biol Chem, 283:28321–28328. 2008.
283.
KawamataH, ManfrediG. Different regulation of wild-type and mutant Cu,Zn superoxide dismutase localization in mammalian mitochondria. Hum Mol Genet, 17:3303–3317. 2008.
284.
KawamuraMF, YamasakiR, KawamuraN, TateishiT, NagaraY, MatsushitaT, OhyagiY, KiraJI. Impaired recruitment of neuroprotective microglia and T cells during acute neuronal injury coincides with increased neuronal vulnerability in an amyotrophic lateral sclerosis model. Exp Neurol, 234:437–445. 2012.
285.
KermanA, LiuHN, CroulS, BilbaoJ, RogaevaE, ZinmanL, RobertsonJ, ChakrabarttyA. Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol, 119:335–344. 2010.
286.
KhanI, OsakaH, StanislausS, CalvoRM, DeerinckT, YakshTL, TaylorP. Nicotinic acetylcholine receptor distribution in relation to spinal neurotransmission pathways. J Comp Neurol, 467:44–59. 2003.
287.
KhareSD, CaplowM, DokholyanNV. The rate and equilibrium constants for a multistep reaction sequence for the aggregation of superoxide dismutase in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A, 101:15094–15099. 2004.
288.
KhareSD, CaplowM, DokholyanNV. FALS mutations in Cu, Zn superoxide dismutase destabilize the dimer and increase dimer dissociation propensity: a large-scale thermodynamic analysis. Amyloid, 13:226–235. 2006.
289.
KieranD, WoodsI, VillungerA, StrasserA, PrehnJH. Deletion of the BH3-only protein puma protects motoneurons from ER stress-induced apoptosis and delays motoneuron loss in ALS mice. Proc Natl Acad Sci U S A, 104:20606–20611. 2007.
KikuchiH, AlmerG, YamashitaS, GueganC, NagaiM, XuZ, SosunovAA, McKhannGM2nd, PrzedborskiS. Spinal cord endoplasmic reticulum stress associated with a microsomal accumulation of mutant superoxide dismutase-1 in an ALS model. Proc Natl Acad Sci U S A, 103:6025–6030. 2006.
292.
KimD, NguyenMD, DobbinMM, FischerA, SananbenesiF, RodgersJT, DelalleI, BaurJA, SuiG, ArmourSM, PuigserverP, SinclairDA, TsaiLH. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. Embo J, 26:3169–3179. 2007.
293.
KimH, KimHY, ChoiMR, HwangS, NamKH, KimHC, HanJS, KimKS, YoonHS, KimSH. Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice. Neurosci Lett, 468:190–194. 2010.
294.
KimSH, ShanwareNP, BowlerMJ, TibbettsRS. Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA. J Biol Chem, 285:34097–34105. 2010.
295.
KimSH, ShiY, HansonKA, WilliamsLM, SakasaiR, BowlerMJ, TibbettsRS. Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1. J Biol Chem, 284:8083–8092. 2009.
296.
KirbyJ, HalliganE, BaptistaMJ, AllenS, HeathPR, HoldenH, BarberSC, LoynesCA, Wood-AllumCA, LunecJ, ShawPJ. Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain, 128:1686–1706. 2005.
297.
KirbyJ, HewamaddumaCA, HartleyJA, NixonHC, EvansH, WadhwaRR, KershawC, IncePG, ShawPJ. Mutations in VAPB are not associated with sporadic ALS. Neurology, 68:1951–1953. 2007.
298.
KloppelC, MichelsC, ZimmerJ, HerrmannJM, RiemerJ. In yeast redistribution of Sod1 to the mitochondrial intermembrane space provides protection against respiration derived oxidative stress. Biochem Biophys Res Commun, 403:114–119. 2010.
299.
KloppelC, SuzukiY, KojerK, PetrungaroC, LongenS, FiedlerS, KellerS, RiemerJ. Mia40-dependent oxidation of cysteines in Domain I of Ccs1 controls its distribution between mitochondria and the cytosol. Mol Biol Cell, 22:3749–3757. 2011.
300.
KohJY, KimDK, HwangJY, KimYH, SeoJH. Antioxidative and proapoptotic effects of riluzole on cultured cortical neurons. J Neurochem, 72:716–723. 1999.
301.
KostrominovaTY. Advanced age-related denervation and fiber-type grouping in skeletal muscle of SOD1 knockout mice. Free Radic Biol Med, 49:1582–1593. 2010.
302.
KressJA, KuhnleinP, WinterP, LudolphAC, KassubekJ, MullerU, SperfeldAD. Novel mutation in the ALS2 gene in juvenile amyotrophic lateral sclerosis. Ann Neurol, 58:800–803. 2005.
303.
KryndushkinD, WicknerRB, ShewmakerF. FUS/TLS forms cytoplasmic aggregates, inhibits cell growth and interacts with TDP-43 in a yeast model of amyotrophic lateral sclerosis. Protein Cell, 2:223–236.
304.
KuhnleinP, JungH, FarkasM, KeskitaloS, IneichenB, JelcicI, PetersenJ, SemmlerA, WellerM, LudolphAC, LinnebankM. The thermolabile variant of 5,10-methylenetetrahydrofolate reductase is a possible risk factor for amyotrophic lateral sclerosis. Amyotroph Lateral Scler, 12:136–139. 2010.
305.
KuhnleinP, SperfeldAD, VanmassenhoveB, Van DeerlinV, LeeVM, TrojanowskiJQ, KretzschmarHA, LudolphAC, NeumannM. Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch Neurol, 65:1185–1189. 2008.
306.
KupershmidtL, WeinrebO, AmitT, MandelS, CarriMT, YoudimMB. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. Faseb J, 23:3766–3779. 2009.
307.
KurodaM, SokJ, WebbL, BaechtoldH, UranoF, YinY, ChungP, de RooijDG, AkhmedovA, AshleyT, RonD. Male sterility and enhanced radiation sensitivity in TLS(-/-) mice. Embo J, 19:453–462. 2000.
308.
KwiatkowskiTJJr., BoscoDA, LeclercAL, TamrazianE, VanderburgCR, RussC, DavisA, GilchristJ, KasarskisEJ, MunsatT, ValdmanisP, RouleauGA, HoslerBA, CortelliP, de JongPJ, YoshinagaY, HainesJL, Pericak-VanceMA, YanJ, TicozziN, SiddiqueT, McKenna-YasekD, SappPC, HorvitzHR, LandersJE, BrownRHJr.Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science, 323:1205–1208. 2009.
309.
LaaksovirtaH, PeuralinnaT, SchymickJC, ScholzSW, LaiSL, MyllykangasL, SulkavaR, JanssonL, HernandezDG, GibbsJR, NallsMA, HeckermanD, TienariPJ, TraynorBJ. Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol, 9:978–985. 2010.
310.
Lagier-TourenneC, ClevelandDW. Rethinking ALS: the FUS about TDP-43. Cell, 136:1001–1004. 2009.
LaiC, XieC, ShimH, ChandranJ, HowellBW, CaiH. Regulation of endosomal motility and degradation by amyotrophic lateral sclerosis 2/alsin. Mol Brain, 2:23. 2009.
313.
LairdAS, Van HoeckeA, De MuynckL, TimmersM, Van den BoschL, Van DammeP, RobberechtW. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS One, 5:e13368. 2010.
314.
LambrechtsD, StorkebaumE, MorimotoM, Del-FaveroJ, DesmetF, MarklundSL, WynsS, ThijsV, AnderssonJ, van MarionI, Al-ChalabiA, BornesS, MussonR, HansenV, BeckmanL, AdolfssonR, PallHS, PratsH, VermeireS, RutgeertsP, KatayamaS, AwataT, LeighN, Lang-LazdunskiL, DewerchinM, ShawC, MoonsL, VlietinckR, MorrisonKE, RobberechtW, Van BroeckhovenC, CollenD, AndersenPM, CarmelietP. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet, 34:383–394. 2003.
LandersJE, MelkiJ, MeiningerV, GlassJD, van den BergLH, van EsMA, SappPC, van VughtPW, McKenna-YasekDM, BlauwHM, ChoTJ, PolakM, ShiL, WillsAM, BroomWJ, TicozziN, SilaniV, OzoguzA, Rodriguez-LeyvaI, VeldinkJH, IvinsonAJ, SarisCG, HoslerBA, Barnes-NessaA, CoutureN, WokkeJH, KwiatkowskiTJJr., OphoffRA, CroninS, HardimanO, DiekstraFP, LeighPN, ShawCE, SimpsonCL, HansenVK, PowellJF, CorciaP, SalachasF, HeathS, GalanP, GeorgesF, HorvitzHR, LathropM, PurcellS, Al-ChalabiA, BrownRHJr.Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A, 106:9004–9009. 2009.
317.
LangkammerC, EnzingerC, QuasthoffS, GrafenauerP, SoellingerM, FazekasF, RopeleS. Mapping of iron deposition in conjunction with assessment of nerve fiber tract integrity in amyotrophic lateral sclerosis. J Magn Reson Imaging, 31:1339–1345. 2010.
318.
LangouK, MoumenA, PellegrinoC, AebischerJ, MedinaI, AebischerP, RaoulC. AAV-mediated expression of wild-type and ALS-linked mutant VAPB selectively triggers death of motoneurons through a Ca2+-dependent ER-associated pathway. J Neurochem, 114:795–809. 2010.
319.
LankaV, CudkowiczM. Therapy development for ALS: lessons learned and path forward. Amyotroph Lateral Scler, 9:131–140. 2008.
320.
LansonNAJr., MaltareA, KingH, SmithR, KimJH, TaylorJP, LloydTE, PandeyUB. A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43. Hum Mol Genet, 20:2510–2523. 2011.
LasieneJ, YamanakaK. Glial cells in amyotrophic lateral sclerosis. Neurol Res Int, 2011:718987. 2011.
323.
LedererCW, TorrisiA, PantelidouM, SantamaN, CavallaroS. Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. BMC Genomics, 8:26. 2007.
324.
LeeJ, KannagiM, FerranteRJ, KowallNW, RyuH. Activation of Ets-2 by oxidative stress induces Bcl-xL expression and accounts for glial survival in amyotrophic lateral sclerosis. Faseb J, 23:1739–1749. 2009.
325.
LenzkenSC, RomeoV, ZolezziF, CorderoF, LamorteG, BonannoD, BiancoliniD, CozzolinoM, PesaresiMG, MaracchioniA, SangesR, AchselT, CarriMT, CalogeroRA, BarabinoSM. Mutant SOD1 and mitochondrial damage alter expression and splicing of genes controlling neuritogenesis in models of neurodegeneration. Hum Mutat, 32:168–182. 2011.
326.
LeporeAC, HaenggeliC, GasmiM, BishopKM, BartusRT, MaragakisNJ, RothsteinJD. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res, 1185:256–265. 2007.
327.
LeporeAC, RauckB, DejeaC, PardoAC, RaoMS, RothsteinJD, MaragakisNJ. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci, 11:1294–1301. 2008.
328.
LergaA, HallierM, DelvaL, OrvainC, GallaisI, MarieJ, Moreau-GachelinF. Identification of an RNA binding specificity for the potential splicing factor TLS. J Biol Chem, 276:6807–6816. 2001.
329.
LevN, IckowiczD, BarhumY, MelamedE, OffenD. DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS. J Mol Neurosci, 38:94–102. 2009.
330.
LiL, ZhangX, LeW. Altered macroautophagy in the spinal cord of SOD1 mutant mice. Autophagy, 4:290–293. 2008.
331.
LiM, OnaVO, GueganC, ChenM, Jackson-LewisV, AndrewsLJ, OlszewskiAJ, StiegPE, LeeJP, PrzedborskiS, FriedlanderRM. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science, 288:335–339. 2000.
332.
LiQ, Vande VeldeC, IsraelsonA, XieJ, BaileyAO, DongMQ, ChunSJ, RoyT, WinerL, YatesJR, CapaldiRA, ClevelandDW, MillerTM. ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import. Proc Natl Acad Sci U S A, 107:21146–21151. 2010.
333.
LiY, RayP, RaoEJ, ShiC, GuoW, ChenX, WoodruffEA3rd, FushimiK, WuJY. A Drosophila model for TDP-43 proteinopathy. Proc Natl Acad Sci U S A, 107:3169–3174. 2010.
334.
LiachkoNF, GuthrieCR, KraemerBC. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci, 30:16208–16219. 2010.
335.
LinMT, BealMF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443:787–795. 2006.
336.
LingSC, AlbuquerqueCP, HanJS, Lagier-TourenneC, TokunagaS, ZhouH, ClevelandDW. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci U S A, 107:13318–13323. 2010.
337.
LinoMM, SchneiderC, CaroniP. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J Neurosci, 22:4825–4832. 2002.
LiuJ, SegalM, YooS, YangGY, KellyM, JamesTL, LittL. Antioxidant effect of ethyl pyruvate in respiring neonatal cerebrocortical slices after H(2)O(2) stress. Neurochem Int, 54:106–110. 2009.
340.
LobsigerCS, BoilleeS, McAlonis-DownesM, KhanAM, FeltriML, YamanakaK, ClevelandDW. Schwann cells expressing dismutase active mutant SOD1 unexpectedly slow disease progression in ALS mice. Proc Natl Acad Sci U S A, 106:4465–4470. 2009.
341.
Lopez-GonzalezR, KuncklesP, VelascoI. Transient recovery in a rat model of familial amyotrophic lateral sclerosis after transplantation of motor neurons derived from mouse embryonic stem cells. Cell Transplant, 18:1171–1181. 2009.
342.
LudolphAC, BendottiC, BlaugrundE, ChioA, GreensmithL, LoefflerJP, MeadR, NiessenHG, PetriS, PradatPF, RobberechtW, RueggM, SchwalenstockerB, StillerD, van den BergL, VieiraF, von HorstenS. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler, 11:38–45. 2010.
343.
LukasTJ, LuoWW, MaoH, ColeN, SiddiqueT. Informatics-assisted protein profiling in a transgenic mouse model of amyotrophic lateral sclerosis. Mol Cell Proteomics, 5:1233–1244. 2006.
MagraneJ, ManfrediG. Mitochondrial function, morphology, and axonal transport in amyotrophic lateral sclerosis. Antioxid Redox Signal, 11:1615–1626. 2009.
349.
MalaspinaA, KaushikN, de BellerocheJ. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J Neurochem, 77:132–145. 2001.
350.
MancusoR, Santos-NogueiraE, OstaR, NavarroX. Electrophysiological analysis of a murine model of motoneuron disease. Clin Neurophysiol, 122:1660–1670. 2011.
MarcuzzoS, ZuccaI, MastropietroA, de RosboNK, CavalcanteP, TartariS, BonannoS, PreiteL, MantegazzaR, BernasconiP. Hind limb muscle atrophy precedes cerebral neuronal degeneration in G93A-SOD1 mouse model of amyotrophic lateral sclerosis: a longitudinal MRI study. Exp Neurol, 231:30–37. 2011.
353.
MarquesVD, BarreiraAA, DavisMB, Abou-SleimanPM, SilvaWAJr., ZagoMA, SobreiraC, FazanV, MarquesWJr.Expanding the phenotypes of the Pro56Ser VAPB mutation: proximal SMA with dysautonomia. Muscle Nerve, 34:731–739. 2006.
MassignanT, CasoniF, BassoM, StefanazziP, BiasiniE, TortaroloM, SalmonaM, GianazzaE, BendottiC, BonettoV. Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse. Biochem Biophys Res Commun, 353:719–725. 2007.
356.
MattiazziM, D'AurelioM, GajewskiCD, MartushovaK, KiaeiM, BealMF, ManfrediG. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem, 277:29626–29633. 2002.
357.
MavlyutovTA, EpsteinML, AndersenKA, Ziskind-ConhaimL, RuohoAE. The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience, 167:247–255. 2011.
358.
McCownTJ. Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther, 11:181–188. 2011.
359.
McDonaldKK, AulasA, DestroismaisonsL, PicklesS, BeleacE, CamuW, RouleauGA, Vande VeldeC. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum Mol Genet, 20:1400–1410. 2011.
McLaughlinRL, PhukanJ, McCormackW, LynchDS, GreenwayM, CroninS, SaundersJ, SlowikA, TomikB, AndersenPM, BradleyDG, JakemanP, HardimanO. Angiogenin levels and ANG genotypes: dysregulation in amyotrophic lateral sclerosis. PLoS One, 5:e15402. 2010.
362.
MeadRJ, BennettEJ, KennerleyAJ, SharpP, SunyachC, KasherP, BerwickJ, PettmannB, BattagliaG, AzzouzM, GriersonA, ShawPJ. Optimised and rapid pre-clinical screening in the SOD1 transgenic mouse model of amyotrophic lateral sclerosis (ALS)PLoS One, 6:e23244. 2011.
363.
MenziesFM, CooksonMR, TaylorRW, TurnbullDM, Chrzanowska-LightowlersZM, DongL, FiglewiczDA, ShawPJ. Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain, 125:1522–1533. 2002.
364.
MeseckeN, TerziyskaN, KozanyC, BaumannF, NeupertW, HellK, HerrmannJM. A disulfide relay system in the intermembrane space of mitochondria that mediates protein import. Cell, 121:1059–1069. 2005.
Miana-MenaFJ, PiedrafitaE, Gonzalez-MingotC, LarrodeP, MunozMJ, Martinez-BallarinE, ReiterRJ, OstaR, GarciaJJ. Levels of membrane fluidity in the spinal cord and the brain in an animal model of amyotrophic lateral sclerosis. J Bioenerg Biomembr, 43:181–186. 2011.
367.
MiguelL, FrebourgT, CampionD, LecourtoisM. Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies. Neurobiol Dis, 41:398–406. 2011.
368.
MillecampsS, BoilleeS, ChabrolE, CamuW, CazeneuveC, SalachasF, PradatPF, Danel-BrunaudV, VandenbergheN, CorciaP, Le ForestierN, LacomblezL, BruneteauG, SeilheanD, BriceA, FeingoldJ, MeiningerV, LeGuernE. Screening of OPTN in French familial amyotrophic lateral sclerosis. Neurobiol Aging, 32:557e11–557 e13. 2011.
369.
MillecampsS, Da BarrocaS, CazeneuveC, SalachasF, PradatPF, Danel-BrunaudV, VandenbergheN, LacomblezL, Le ForestierN, BruneteauG, CamuW, BriceA, MeiningerV, LeGuernE. Questioning on the role of D amino acid oxidase in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A, 107:E107author reply E1082010.
370.
MillerRG, MitchellJD, LyonM, MooreDH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)Amyotroph Lateral Scler Other Motor Neuron Disord, 4:191–206. 2003.
371.
MillerRG, MooreDH, ForshewDA, KatzJS, BarohnRJ, ValanM, BrombergMB, GoslinKL, GravesMC, McCluskeyLF, McVeyAL, MozaffarT, FlorenceJM, PestronkA, RossM, SimpsonEP, AppelSH. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology, 77:973–979. 2011.
372.
MillerTM, KimSH, YamanakaK, HesterM, UmapathiP, ArnsonH, RizoL, MendellJR, GageFH, ClevelandDW, KasparBK. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A, 103:19546–19551. 2006.
373.
MitchellJ, PaulP, ChenHJ, MorrisA, PaylingM, FalchiM, HabgoodJ, PanoutsouS, WinklerS, TisatoV, HajitouA, SmithB, VanceC, ShawC, MazarakisND, de BellerocheJ. Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc Natl Acad Sci U S A, 107:7556–7561. 2010.
374.
MitchellRM, SimmonsZ, BeardJL, StephensHE, ConnorJR. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve, 42:95–103. 2010.
375.
Mitne-NetoM, Machado-CostaM, MarchettoMC, BengtsonMH, JoazeiroCA, TsudaH, BellenHJ, SilvaHC, OliveiraAS, LazarM, MuotriAR, ZatzM. Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. Hum Mol Genet, 20:3642–3652. 2011.
376.
MizunoY, AmariM, TakatamaM, AizawaH, MiharaB, OkamotoK. Immunoreactivities of p62, an ubiqutin-binding protein, in the spinal anterior horn cells of patients with amyotrophic lateral sclerosis. J Neurol Sci, 249:13–18. 2006.
377.
MoisseK, VolkeningK, Leystra-LantzC, WelchI, HillT, StrongMJ. Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. Brain Res, 1249:202–211. 2009.
378.
MorahanJM, PamphlettR. Amyotrophic lateral sclerosis and exposure to environmental toxins: an Australian case-control study. Neuroepidemiology, 27:130–135. 2006.
379.
MorahanJM, YuB, TrentRJ, PamphlettR. Genetic susceptibility to environmental toxicants in ALS. Am J Med Genet B Neuropsychiatr Genet, 144B:885–890. 2007.
380.
MoreiraMC, KlurS, WatanabeM, NemethAH, Le BerI, MonizJC, TranchantC, AubourgP, TazirM, ScholsL, PandolfoM, SchulzJB, PougetJ, CalvasP, Shizuka-IkedaM, ShojiM, TanakaM, IzattL, ShawCE, M'ZahemA, DunneE, BomontP, BenhassineT, BouslamN, StevaninG, BriceA, GuimaraesJ, MendoncaP, BarbotC, CoutinhoP, SequeirosJ, DurrA, WarterJM, KoenigM. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet, 36:225–227. 2004.
381.
MorelandRJ, DresserME, RodgersJS, RoeBA, ConawayJW, ConawayRC, HanasJS. Identification of a transcription factor IIIA-interacting protein. Nucleic Acids Res, 28:1986–1993. 2000.
382.
MorenoS, NardacciR, CiminiA, CeruMP. Immunocytochemical localization of D-amino acid oxidase in rat brain. J Neurocytol, 28:169–185. 1999.
383.
MorikawaK, ShimokawaH, MatobaT, KubotaH, AkaikeT, TalukderMA, HatanakaM, FujikiT, MaedaH, TakahashiS, TakeshitaA. Pivotal role of Cu,Zn-superoxide dismutase in endothelium-dependent hyperpolarization. J Clin Invest, 112:1871–1879. 2003.
384.
MorimotoN, NagaiM, OhtaY, MiyazakiK, KurataT, MorimotoM, MurakamiT, TakehisaY, IkedaY, KamiyaT, AbeK. Increased autophagy in transgenic mice with a G93A mutant SOD1 gene. Brain Res, 1167:112–117. 2007.
385.
MoroN, SuttonRL. Beneficial effects of sodium or ethyl pyruvate after traumatic brain injury in the rat. Exp Neurol, 225:391–401. 2010.
386.
MourelatosZ, GonatasNK, StieberA, GurneyME, Dal CantoMC. The Golgi apparatus of spinal cord motor neurons in transgenic mice expressing mutant Cu,Zn superoxide dismutase becomes fragmented in early, preclinical stages of the disease. Proc Natl Acad Sci U S A, 93:5472–5477. 1996.
387.
MunchC, O'BrienJ, BertolottiA. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci U S A, 108:3548–3553. 2011.
NaganoI, ShioteM, MurakamiT, KamadaH, HamakawaY, MatsubaraE, YokoyamaM, MoritazK, ShojiM, AbeK. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol Res, 27:768–772. 2005.
391.
NagaseT, NakayamaM, NakajimaD, KikunoR, OharaO. Prediction of the coding sequences of unidentified human genes. XX. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res, 8:85–95. 2001.
392.
NagataT, IlievaH, MurakamiT, ShioteM, NaraiH, OhtaY, HayashiT, ShojiM, AbeK. Increased ER stress during motor neuron degeneration in a transgenic mouse model of amyotrophic lateral sclerosis. Neurol Res, 29:767–771. 2007.
393.
NardoG, PozziS, MantovaniS, GarbelliS, MarinouK, BassoM, MoraG, BendottiC, BonettoV. Nitroproteomics of peripheral blood mononuclear cells from patients and a rat model of ALS. Antioxid Redox Signal, 11:1559–1567. 2009.
394.
NassifM, MatusS, CastilloK, HetzC. Amyotrophic lateral sclerosis pathogenesis: a journey through the secretory pathway. Antioxid Redox Signal, 13:1955–1989. 2010.
395.
NeumannM, RademakersR, RoeberS, BakerM, KretzschmarHA, MackenzieIR. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain, 132:2922–2931. 2009.
NishimotoY, ItoD, YagiT, NiheiY, TsunodaY, SuzukiN. Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43. J Biol Chem, 285:608–619. 2010.
398.
NishimuraAL, Mitne-NetoM, SilvaHC, Richieri-CostaA, MiddletonS, CascioD, KokF, OliveiraJR, GillingwaterT, WebbJ, SkehelP, ZatzM. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet, 75:822–831. 2004.
399.
NonakaT, KametaniF, AraiT, AkiyamaH, HasegawaM. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet, 18:3353–3364. 2009.
400.
NousiainenHO, KestilaM, PakkasjarviN, HonkalaH, KuureS, TallilaJ, VuopalaK, IgnatiusJ, HervaR, PeltonenL. Mutations in mRNA export mediator GLE1 result in a fetal motoneuron disease. Nat Genet, 40:155–157. 2008.
401.
O'BrienKM, DirmeierR, EngleM, PoytonRO. Mitochondrial protein oxidation in yeast mutants lacking manganese-(MnSOD) or copper- and zinc-containing superoxide dismutase (CuZnSOD): evidence that MnSOD and CuZnSOD have both unique and overlapping functions in protecting mitochondrial proteins from oxidative damage. J Biol Chem, 279:51817–51827. 2004.
402.
O'Donnell-TormeyJ, NathanCF, LanksK, DeBoerCJ, de la HarpeJ. Secretion of pyruvate. An antioxidant defense of mammalian cells. J Exp Med, 165:500–514. 1987.
OffenD, BarhumY, MelamedE, EmbacherN, SchindlerC, RansmayrG. Spinal cord mRNA profile in patients with ALS: comparison with transgenic mice expressing the human SOD-1 mutant. J Mol Neurosci, 38:85–93. 2009.
405.
OhYK, ShinKS, YuanJ, KangSJ. Superoxide dismutase 1 mutants related to amyotrophic lateral sclerosis induce endoplasmic stress in neuro2a cells. J Neurochem, 104:993–1005. 2008.
406.
OhnishiS, ItoH, SuzukiY, AdachiY, WateR, ZhangJ, NakanoS, KusakaH, IkeharaS. Intra-bone marrow-bone marrow transplantation slows disease progression and prolongs survival in G93A mutant SOD1 transgenic mice, an animal model mouse for amyotrophic lateral sclerosis. Brain Res, 1296:216–224. 2009.
407.
Okado-MatsumotoA, FridovichI. Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu,Zn-SOD in mitochondria. J Biol Chem, 276:38388–38393. 2001.
408.
OlsenMK, RoberdsSL, EllerbrockBR, FleckTJ, McKinleyDK, GurneyME. Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann Neurol, 50:730–740. 2001.
OrrHT. FTD and ALS: genetic ties that bind. Neuron, 72:189–190. 2011.
411.
OtomoA, HadanoS, OkadaT, MizumuraH, KunitaR, NishijimaH, Showguchi-MiyataJ, YanagisawaY, KohikiE, SugaE, YasudaM, OsugaH, NishimotoT, NarumiyaS, IkedaJE. ALS2, a novel guanine nucleotide exchange factor for the small GTPase Rab5, is implicated in endosomal dynamics. Hum Mol Genet, 12:1671–1687. 2003.
412.
OuSH, WuF, HarrichD, Garcia-MartinezLF, GaynorRB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol, 69:3584–3596. 1995.
413.
OyanagiK, YamazakiM, TakahashiH, WatabeK, WadaM, KomoriT, MoritaT, MizutaniT. Spinal anterior horn cells in sporadic amyotrophic lateral sclerosis show ribosomal detachment from, and cisternal distention of the rough endoplasmic reticulum. Neuropathol Appl Neurobiol, 34:650–658. 2008.
414.
PanzeriC, De PalmaC, MartinuzziA, DagaA, De PoloG, BresolinN, MillerCC, TudorEL, ClementiE, BassiMT. The first ALS2 missense mutation associated with JPLS reveals new aspects of alsin biological function. Brain, 129:1710–1719. 2006.
415.
PapadeasST, KraigSE, O'BanionC, LeporeAC, MaragakisNJ. Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo. Proc Natl Acad Sci U S A, 108:17803–17808. 2011.
416.
ParkS, KimHT, YunS, KimIS, LeeJ, LeeIS, ParkKI. Growth factor-expressing human neural progenitor cell grafts protect motor neurons but do not ameliorate motor performance and survival in ALS mice. Exp Mol Med, 41:487–500. 2009.
417.
PasinelliP, BelfordME, LennonN, BacskaiBJ, HymanBT, TrottiD, BrownRHJr.Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron, 43:19–30. 2004.
418.
PaubelA, VioletteJ, AmyM, PralineJ, MeiningerV, CamuW, CorciaP, AndresCR, Vourc'hP. Mutations of the ANG gene in French patients with sporadic amyotrophic lateral sclerosis. Arch Neurol, 65:1333–1336. 2008.
PetriS, KiaeiM, KipianiK, ChenJ, CalingasanNY, CrowJP, BealMF. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis, 22:40–49. 2006.
422.
PiepersS, VeldinkJH, de JongSW, van der TweelI, van der PolWL, UijtendaalEV, SchelhaasHJ, SchefferH, de VisserM, de JongJM, WokkeJH, GroeneveldGJ, van den BergLH. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol, 66:227–234. 2009.
423.
PizzasegolaC, CaronI, DalenoC, RonchiA, MinoiaC, CarriMT, BendottiC. Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotroph Lateral Scler, 10:221–228. 2009.
424.
PollariE, SavchenkoE, JaronenM, KanninenK, MalmT, WojciechowskiS, AhtoniemiT, GoldsteinsG, GiniatullinaR, GiniatullinR, KoistinahoJ, MaggaJ. Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis. J Neuroinflammation, 8:74. 2011.
425.
PolymenidouM, Lagier-TourenneC, HuttKR, HuelgaSC, MoranJ, LiangTY, LingSC, SunE, WancewiczE, MazurC, KordasiewiczH, SedaghatY, DonohueJP, ShiueL, BennettCF, YeoGW, ClevelandDW. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci, 14:459–468. 2011.
426.
PowersCA, MathurM, RaakaBM, RonD, SamuelsHH. TLS (translocated-in-liposarcoma) is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol Endocrinol, 12:4–18. 1998.
427.
PradatPF, DubourgO, de TapiaM, di ScalaF, DupuisL, LengletT, BruneteauG, SalachasF, LacomblezL, CorvolJC, DemouginP, PrimigM, MeiningerV, LoefflerJP, Gonzalez de AguilarJL. Muscle gene expression is a marker of amyotrophic lateral sclerosis severity. Neurodegener Dis, 9:38–52. 2012.
428.
PrecourtLP, AmreD, DenisMC, LavoieJC, DelvinE, SeidmanE, LevyE. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis, 214:20–36. 2011.
429.
ProctorEA, DingF, DokholyanNV. Structural and thermodynamic effects of post-translational modifications in mutant and wild type Cu, Zn superoxide dismutase. J Mol Biol, 408:555–567. 2011.
430.
ProescherJB, SonM, ElliottJL, CulottaVC. Biological effects of CCS in the absence of SOD1 enzyme activation: implications for disease in a mouse model for ALS. Hum Mol Genet, 17:1728–1737. 2008.
431.
PrudencioM, HartPJ, BorcheltDR, AndersenPM. Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum Mol Genet, 18:3217–3226. 2009.
432.
PrusinerSB. Prions. Proc Natl Acad Sci U S A, 95:13363–13383. 1998.
433.
QureshiM, BrownRHJr., RogersJT, CudkowiczME. Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis. Open Neurol J, 2:51–54. 2008.
434.
QureshiM, SchoenfeldDA, PaliwalY, ShuiA, CudkowiczME. The natural history of ALS is changing: improved survival. Amyotroph Lateral Scler, 10:324–331. 2009.
435.
RabbittsTH, ForsterA, LarsonR, NathanP. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet, 4:175–180. 1993.
436.
RakhitR, RobertsonJ, VeldeCV, HorneP, RuthDM, GriffinJ, ClevelandDW, CashmanNR, ChakrabarttyA. An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat Med, 13:754–759. 2007.
437.
RalphGS, RadcliffePA, DayDM, CarthyJM, LerouxMA, LeeDC, WongLF, BilslandLG, GreensmithL, KingsmanSM, MitrophanousKA, MazarakisND, AzzouzM. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med, 11:429–433. 2005.
438.
RaoulC, Abbas-TerkiT, BensadounJC, GuillotS, HaaseG, SzulcJ, HendersonCE, AebischerP. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med, 11:423–428. 2005.
439.
RatnaparkhiA, LawlessGM, SchweizerFE, GolshaniP, JacksonGR. A Drosophila model of ALS: human ALS-associated mutation in VAP33A suggests a dominant negative mechanism. PLoS One, 3:e2334. 2008.
440.
ReddehaseS, GrumbtB, NeupertW, HellK. The disulfide relay system of mitochondria is required for the biogenesis of mitochondrial Ccs1 and Sod1. J Mol Biol, 385:331–338. 2009.
441.
RedlerRL, WilcoxKC, ProctorEA, FeeL, CaplowM, DokholyanNV. Glutathionylation at Cys-111 induces dissociation of wild type and FALS mutant SOD1 dimers. Biochemistry, 50:7057–7066. 2011.
ReyesNA, FisherJK, AustgenK, VandenBergS, HuangEJ, OakesSA. Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis. J Clin Invest, 120:3673–3679. 2010.
RezaieT, SarfaraziM. Molecular cloning, genomic structure, and protein characterization of mouse optineurin. Genomics, 85:131–138. 2005.
446.
RichardsCI, SrinivasanR, XiaoC, MackeyED, MiwaJM, LesterHA. Trafficking of {alpha}4* nicotinic receptors revealed by superecliptic phluorin: effects of a {beta}4 amyotrophic lateral sclerosis-associated mutation and chronic exposure to nicotine. J Biol Chem, 286:31241–31249. 2011.
447.
RitsonGP, CusterSK, FreibaumBD, GuintoJB, GeffelD, MooreJ, TangW, WintonMJ, NeumannM, TrojanowskiJQ, LeeVM, FormanMS, TaylorJP. TDP-43 mediates degeneration in a novel drosophila model of disease caused by mutations in VCP/p97. J Neurosci, 30:7729–7739. 2010.
448.
RosenDR, SiddiqueT, PattersonD, FiglewiczDA, SappP, HentatiA, DonaldsonD, GotoJ, O'ReganJP, DengHXet al.Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 362:59–62. 1993.
449.
RothsteinJD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol, 65,Suppl 1:S3–S9. 2009.
450.
RothsteinJD, MartinLJ, KunclRW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med, 326:1464–1468. 1992.
451.
RuddyDM, PartonMJ, Al-ChalabiA, LewisCM, VanceC, SmithBN, LeighPN, PowellJF, SiddiqueT, MeyjesEP, BaasF, de JongV, ShawCE. Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q. Am J Hum Genet, 73:390–396. 2003.
452.
RudgeSA, AndersonDM, EmrSD. Vacuole size control: regulation of PtdIns(3,5)P2 levels by the vacuole-associated Vac14-Fig4 complex, a PtdIns(3,5)P2-specific phosphatase. Mol Biol Cell, 15:24–36. 2004.
RybergH, AnJ, DarkoS, LustgartenJL, JaffaM, GopalakrishnanV, LacomisD, CudkowiczM, BowserR. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve, 42:104–111. 2010.
455.
SabatelliM, EusebiF, Al-ChalabiA, ConteA, MadiaF, LuigettiM, MancusoI, LimatolaC, TrettelF, SobreroF, Di AngelantonioS, GrassiF, Di CastroA, MoriconiC, FucileS, LattanteS, MarangiG, MurdoloM, OrteschiD, Del GrandeA, TonaliP, NeriG, ZollinoM. Rare missense variants of neuronal nicotinic acetylcholine receptor altering receptor function are associated with sporadic amyotrophic lateral sclerosis. Hum Mol Genet, 18:3997–4006. 2009.
456.
SappPC, HoslerBA, McKenna-YasekD, ChinW, GannA, GeniseH, GorensteinJ, HuangM, SailerW, SchefflerM, ValeskyM, HainesJL, Pericak-VanceM, SiddiqueT, HorvitzHR, BrownRHJr.Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am J Hum Genet, 73:397–403. 2003.
457.
SargsyanSA, BlackburnDJ, BarberSC, GrosskreutzJ, De VosKJ, MonkPN, ShawPJ. A comparison of in vitro properties of resting SOD1 transgenic microglia reveals evidence of reduced neuroprotective function. BMC Neurosci, 12:91. 2011.
458.
SarisCG, HorvathS, van VughtPW, van EsMA, BlauwHM, FullerTF, LangfelderP, DeYoungJ, WokkeJH, VeldinkJH, van den BergLH, OphoffRA. Weighted gene co-expression network analysis of the peripheral blood from Amyotrophic Lateral Sclerosis patients. BMC Genomics, 10:405. 2009.
459.
SasakiS. Endoplasmic reticulum stress in motor neurons of the spinal cord in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol, 69:346–355. 2010.
460.
SasakiS. Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol, 70:349–359. 2011.
461.
SasakiS, WaritaH, MurakamiT, ShibataN, KomoriT, AbeK, KobayashiM, IwataM. Ultrastructural study of aggregates in the spinal cord of transgenic mice with a G93A mutant SOD1 gene. Acta Neuropathol, 109:247–255. 2005.
462.
SauD, De BiasiS, Vitellaro-ZuccarelloL, RisoP, GuarnieriS, PorriniM, SimeoniS, CrippaV, OnestoE, PalazzoloI, RusminiP, BolzoniE, BendottiC, PolettiA. Mutation of SOD1 in ALS: a gain of a loss of function. Hum Mol Genet, 16:1604–1618. 2007.
463.
SaxenaS, CabuyE, CaroniP. A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nat Neurosci, 12:627–636. 2009.
464.
SchmalbachS, PetriS. Histone deacetylation and motor neuron degeneration. CNS Neurol Disord Drug Targets, 9:279–284. 2010.
465.
SchmidtO, PfannerN, MeisingerC. Mitochondrial protein import: from proteomics to functional mechanisms. Nat Rev Mol Cell Biol, 11:655–667. 2010.
466.
SchmidtS, KweeLC, AllenKD, OddoneEZ. Association of ALS with head injury, cigarette smoking and APOE genotypes. J Neurol Sci, 291:22–29. 2010.
467.
ScottS, KranzJE, ColeJ, LincecumJM, ThompsonK, KellyN, BostromA, TheodossJ, Al-NakhalaBM, VieiraFG, RamasubbuJ, HeywoodJA. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler, 9:4–15. 2008.
SeibenhenerML, BabuJR, GeethaT, WongHC, KrishnaNR, WootenMW. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol, 24:8055–8068. 2004.
470.
SendtnerM, HoltmannB, KolbeckR, ThoenenH, BardeYA. Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section. Nature, 360:757–759. 1992.
471.
SendtnerM, SchmalbruchH, StockliKA, CarrollP, KreutzbergGW, ThoenenH. Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature, 358:502–504. 1992.
ShanX, ChiangPM, PriceDL, WongPC. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc Natl Acad Sci U S A, 107:16325–16330. 2010.
474.
ShawBF, ValentineJS. How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein?Trends Biochem Sci, 32:78–85. 2007.
475.
ShenH, HuX, LiuC, WangS, ZhangW, GaoH, StetlerRA, GaoY, ChenJ. Ethyl pyruvate protects against hypoxic-ischemic brain injury via anti-cell death and anti-inflammatory mechanisms. Neurobiol Dis, 37:711–722. 2010.
476.
ShenX, YingH, QiuY, ParkJS, ShyamR, ChiZL, IwataT, YueBY. Processing of optineurin in neuronal cells. J Biol Chem, 286:3618–3629. 2011.
477.
SiddiqA, AyoubIA, ChavezJC, AminovaL, ShahS, LaMannaJC, PattonSM, ConnorJR, ChernyRA, VolitakisI, BushAI, LangsetmoI, SeeleyT, GunzlerV, RatanRR. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem, 280:41732–41743. 2005.
478.
SiddiqueT, FiglewiczDA, Pericak-VanceMA, HainesJL, RouleauG, JeffersAJ, SappP, HungWY, BeboutJ, McKenna-YasekDet al.Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med, 324:1381–1384. 1991.
479.
SiderisDP, TokatlidisK. Oxidative protein folding in the mitochondrial intermembrane space. Antioxid Redox Signal, 13:1189–1204. 2010.
480.
SimpsonCL, LemmensR, MiskiewiczK, BroomWJ, HansenVK, van VughtPW, LandersJE, SappP, Van Den BoschL, KnightJ, NealeBM, TurnerMR, VeldinkJH, OphoffRA, TripathiVB, BelezaA, ShahMN, ProitsiP, Van HoeckeA, CarmelietP, HorvitzHR, LeighPN, ShawCE, van den BergLH, ShamPC, PowellJF, VerstrekenP, BrownRHJr., RobberechtW, Al-ChalabiA. Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Hum Mol Genet, 18:472–481. 2009.
SleegersK, BrouwersN, Maurer-StrohS, van EsMA, Van DammeP, van VughtPW, van der ZeeJ, SerneelsS, De PooterT, Van den BroeckM, CrutsM, SchymkowitzJ, De JongheP, RousseauF, van den BergLH, RobberechtW, Van BroeckhovenC. Progranulin genetic variability contributes to amyotrophic lateral sclerosis. Neurology, 71:253–259. 2008.
483.
SnyderBR, GraySJ, QuachET, HuangJW, LeungCH, SamulskiRJ, BoulisNM, FedericiT. Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther, 22:1129–1135. 2011.
484.
SnyderSH, KimPM. D-amino acids as putative neurotransmitters: focus on D-serine. Neurochem Res, 25:553–560. 2000.
485.
SofolaOA, JinP, QinY, DuanR, LiuH, de HaroM, NelsonDL, BotasJ. RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron, 55:565–571. 2007.
486.
SonM, FuQ, PuttaparthiK, MatthewsCM, ElliottJL. Redox susceptibility of SOD1 mutants is associated with the differential response to CCS over-expression in vivo. Neurobiol Dis, 34:155–162. 2009.
487.
SorensonEJ, WindbankAJ, MandrekarJN, BamletWR, AppelSH, ArmonC, BarkhausPE, BoschP, BoylanK, DavidWS, FeldmanE, GlassJ, GutmannL, KatzJ, KingW, LucianoCA, McCluskeyLF, NashS, NewmanDS, PascuzziRM, PioroE, SamsLJ, ScelsaS, SimpsonEP, SubramonySH, TiryakiE, ThorntonCA. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology, 71:1770–1775. 2008.
SouthgateL, DafouD, HoyleJ, LiN, KinningE, CritchleyP, NemethAH, TalbotK, BinduPS, SinhaS, TalyAB, RaghavendraS, MullerF, MaherER, TrembathRC. Novel SPG11 mutations in Asian kindreds and disruption of spatacsin function in the zebrafish. Neurogenetics, 11:379–389. 2010.
StaM, Sylva-SteenlandRM, CasulaM, de JongJM, TroostD, AronicaE, BaasF. Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol Dis, 42:211–220. 2011.
492.
StallingsNR, PuttaparthiK, LutherCM, BurnsDK, ElliottJL. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol Dis, 40:404–414. 2010.
493.
StathopulosPB, RumfeldtJA, KarbassiF, SiddallCA, LepockJR, MeieringEM. Calorimetric analysis of thermodynamic stability and aggregation for apo and holo amyotrophic lateral sclerosis-associated Gly-93 mutants of superoxide dismutase. J Biol Chem, 281:6184–6193. 2006.
494.
SteinleinOK. Genetic disorders caused by mutated acetylcholine receptors. Life Sci, 80:2186–2190. 2007.
495.
StevaninG, SantorelliFM, AzzedineH, CoutinhoP, ChomilierJ, DenoraPS, MartinE, Ouvrard-HernandezAM, TessaA, BouslamN, LossosA, CharlesP, LoureiroJL, ElleuchN, ConfavreuxC, CruzVT, RubergM, LeguernE, GridD, TazirM, FontaineB, FillaA, BertiniE, DurrA, BriceA. Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet, 39:366–372. 2007.
496.
StieberA, GonatasJO, CollardJ, MeierJ, JulienJ, SchweitzerP, GonatasNK. The neuronal Golgi apparatus is fragmented in transgenic mice expressing a mutant human SOD1, but not in mice expressing the human NF-H gene. J Neurol Sci, 173:63–72. 2000.
497.
StieberA, GonatasJO, MooreJS, BantlyA, YimHS, YimMB, GonatasNK. Disruption of the structure of the Golgi apparatus and the function of the secretory pathway by mutants G93A and G85R of Cu, Zn superoxide dismutase (SOD1) of familial amyotrophic lateral sclerosis. J Neurol Sci, 219:45–53. 2004.
498.
StorchA, BurkhardtK, LudolphAC, SchwarzJ. Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J Neurochem, 75:2259–2269. 2000.
499.
StrongMJ, VolkeningK, HammondR, YangW, StrongW, Leystra-LantzC, ShoesmithC. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci, 35:320–327. 2007.
500.
SubramanianV, CrabtreeB, AcharyaKR. Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension/pathfinding and survival of motor neurons. Hum Mol Genet, 17:130–149. 2008.
501.
SudhakarC, NagabhushanaA, JainN, SwarupG. NF-kappaB mediates tumor necrosis factor alpha-induced expression of optineurin, a negative regulator of NF-kappaB. PLoS One, 4:e5114. 2009.
502.
SugaiF, YamamotoY, MiyaguchiK, ZhouZ, SumiH, HamasakiT, GotoM, SakodaS. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci, 20:3179–3183. 2004.
503.
SugiharaK, MaruyamaH, KamadaM, MorinoH, KawakamiH. Screening for OPTN mutations in amyotrophic lateral sclerosis in a mainly Caucasian population. Neurobiol Aging, 32:1923e9–1923 e10. 2011.
504.
SunZ, DiazZ, FangX, HartMP, ChesiA, ShorterJ, GitlerAD. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol, 9:e1000614. 2011.
505.
SuraweeraA, BecherelOJ, ChenP, RundleN, WoodsR, NakamuraJ, GateiM, CriscuoloC, FillaA, ChessaL, FusserM, EpeB, GuevenN, LavinMF. Senataxin, defective in ataxia oculomotor apraxia type 2, is involved in the defense against oxidative DNA damage. J Cell Biol, 177:969–979. 2007.
506.
SuraweeraA, LimY, WoodsR, BirrellGW, NasimT, BecherelOJ, LavinMF. Functional role for senataxin, defective in ataxia oculomotor apraxia type 2, in transcriptional regulation. Hum Mol Genet, 18:3384–3396. 2009.
507.
SussmuthSD, SperfeldAD, HinzA, BrettschneiderJ, EndruhnS, LudolphAC, TumaniH. CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology, 74:982–987. 2010.
508.
SutedjaNA, FischerK, VeldinkJH, van der HeijdenGJ, KromhoutH, HeederikD, HuismanMH, WokkeJJ, van den BergLH. What we truly know about occupation as a risk factor for ALS: a critical and systematic review. Amyotroph Lateral Scler, 10:295–301. 2009.
509.
SutedjaNA, VeldinkJH, FischerK, KromhoutH, HeederikD, HuismanMH, WokkeJH, van den BergLH. Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler, 10:302–309. 2009.
510.
SuzukiH, LeeK, MatsuokaM. TDP-43-induced death is associated with altered regulation of BIM and Bcl-xL and attenuated by caspase-mediated TDP-43 cleavage. J Biol Chem, 286:13171–13183. 2011.
511.
SuzukiM, McHughJ, TorkC, ShelleyB, HayesA, BellantuonoI, AebischerP, SvendsenCN. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther, 16:2002–2010. 2008.
512.
SuzukiM, McHughJ, TorkC, ShelleyB, KleinSM, AebischerP, SvendsenCN. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One, 2:e689. 2007.
513.
SwarupV, PhaneufD, BareilC, RobertsonJ, RouleauGA, KrizJ, JulienJP. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain, 134:2610–2626. 2011.
514.
TakahashiK, YamanakaS. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126:663–676. 2006.
515.
TakeuchiH, KobayashiY, IshigakiS, DoyuM, SobueG. Mitochondrial localization of mutant superoxide dismutase 1 triggers caspase-dependent cell death in a cellular model of familial amyotrophic lateral sclerosis. J Biol Chem, 277:50966–50972. 2002.
516.
TanAY, ManleyJL. The TET family of proteins: functions and roles in disease. J Mol Cell Biol, 1:82–92. 2009.
TobisawaS, HozumiY, ArawakaS, KoyamaS, WadaM, NagaiM, AokiM, ItoyamaY, GotoK, KatoT. Mutant SOD1 linked to familial amyotrophic lateral sclerosis, but not wild-type SOD1, induces ER stress in COS7 cells and transgenic mice. Biochem Biophys Res Commun, 303:496–503. 2003.
525.
ToddPK, PaulsonHL. RNA-mediated neurodegeneration in repeat expansion disorders. Ann Neurol, 67:291–300. 2010.
526.
TodoneF, VanoniMA, MozzarelliA, BolognesiM, CodaA, CurtiB, MatteviA. Active site plasticity in D-amino acid oxidase: a crystallographic analysis. Biochemistry, 36:5853–5860. 1997.
527.
TollerveyJR, CurkT, RogeljB, BrieseM, CeredaM, KayikciM, KonigJ, HortobagyiT, NishimuraAL, ZupunskiV, PataniR, ChandranS, RotG, ZupanB, ShawCE, UleJ. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci, 14:452–458. 2011.
528.
ToppJD, GrayNW, GerardRD, HorazdovskyBF. Alsin is a Rab5 and Rac1 guanine nucleotide exchange factor. J Biol Chem, 279:24612–24623. 2004.
529.
TowneC, RaoulC, SchneiderBL, AebischerP. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther, 16:1018–1025. 2008.
530.
TowneC, SchneiderBL, KieranD, RedmondDEJr., AebischerP. Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther, 17:141–146. 2010.
531.
TowneC, SetolaV, SchneiderBL, AebischerP. Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice. Mol Ther, 19:274–283. 2011.
532.
TraynorBJ, BruijnL, ConwitR, BealF, O'NeillG, FaganSC, CudkowiczME. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology, 67:20–27. 2006.
TsaiKJ, YangCH, FangYH, ChoKH, ChienWL, WangWT, WuTW, LinCP, FuWM, ShenCK. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J Exp Med, 207:1661–1673. 2010.
535.
TurnerBJ, AckerleyS, DaviesKE, TalbotK. Dismutase-competent SOD1 mutant accumulation in myelinating Schwann cells is not detrimental to normal or transgenic ALS model mice. Hum Mol Genet, 19:815–824. 2010.
536.
TurnerBJ, AtkinJD, FargMA, ZangDW, RembachA, LopesEC, PatchJD, HillAF, CheemaSS. Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis. J Neurosci, 25:108–117. 2005.
537.
TurnerMR, AbisgoldJ, YeatesDG, TalbotK, GoldacreMJ. Head and other physical trauma requiring hospitalisation is not a significant risk factor in the development of ALS. J Neurol Sci, 288:45–48. 2010.
UranishiH, TetsukaT, YamashitaM, AsamitsuK, ShimizuM, ItohM, OkamotoT. Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated transcription as a coactivator. J Biol Chem, 276:13395–13401. 2001.
540.
UrushitaniM, EzziSA, JulienJP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A, 104:2495–2500. 2007.
541.
UrushitaniM, KurisuJ, TsukitaK, TakahashiR. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J Neurochem, 83:1030–1042. 2002.
van BlitterswijkM, van VughtPW, van EsMA, SchelhaasHJ, van der KooiAJ, de VisserM, VeldinkJH, van den BergLH. Novel optineurin mutations in sporadic amyotrophic lateral sclerosis patients. Neurobiol Aging, 33:1016.e1–1016.e7. 2012.
544.
Van DammeP, VeldinkJH, van BlitterswijkM, CorveleynA, van VughtPW, ThijsV, DuboisB, MatthijsG, van den BergLH, RobberechtW. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology, 76:2066–2072. 2011.
545.
van EsMA, DiekstraFP, VeldinkJH, BaasF, BourquePR, SchelhaasHJ, StrengmanE, HennekamEA, LindhoutD, OphoffRA, van den BergLH. A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. Neurology, 72:287–288. 2009.
546.
van EsMA, Van VughtPW, BlauwHM, FrankeL, SarisCG, AndersenPM, Van Den BoschL, de JongSW, van ’t SlotR, BirveA, LemmensR, de JongV, BaasF, SchelhaasHJ, SleegersK, Van BroeckhovenC, WokkeJH, WijmengaC, RobberechtW, VeldinkJH, OphoffRA, van den BergLH. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol, 6:869–877. 2007.
547.
van EsMA, VeldinkJH, SarisCG, BlauwHM, van VughtPW, BirveA, LemmensR, SchelhaasHJ, GroenEJ, HuismanMH, van der KooiAJ, de VisserM, DahlbergC, EstradaK, RivadeneiraF, HofmanA, ZwartsMJ, van DoormaalPT, RujescuD, StrengmanE, GieglingI, MugliaP, TomikB, SlowikA, UitterlindenAG, HendrichC, WaibelS, MeyerT, LudolphAC, GlassJD, PurcellS, CichonS, NothenMM, WichmannHE, SchreiberS, VermeulenSH, KiemeneyLA, WokkeJH, CroninS, McLaughlinRL, HardimanO, FumotoK, PasterkampRJ, MeiningerV, MelkiJ, LeighPN, ShawCE, LandersJE, Al-ChalabiA, BrownRHJr., RobberechtW, AndersenPM, OphoffRA, van den BergLH. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet, 41:1083–1087. 2009.
548.
VanacoreN, CoccoP, FaddaD, DosemeciM. Job strain, hypoxia and risk of amyotrophic lateral sclerosis: results from a death certificate study. Amyotroph Lateral Scler, 11:430–434. 2010.
549.
VanceC, RogeljB, HortobagyiT, De VosKJ, NishimuraAL, SreedharanJ, HuX, SmithB, RuddyD, WrightP, GanesalingamJ, WilliamsKL, TripathiV, Al-SarajS, Al-ChalabiA, LeighPN, BlairIP, NicholsonG, de BellerocheJ, GalloJM, MillerCC, ShawCE. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science, 323:1208–1211. 2009.
550.
Vande VeldeC, McDonaldKK, BoukhedimiY, McAlonis-DownesM, LobsigerCS, Bel HadjS, ZandonaA, JulienJP, ShahSB, ClevelandDW. Misfolded SOD1 associated with motor neuron mitochondria alters mitochondrial shape and distribution prior to clinical onset. PLoS One, 6:e22031. 2011.
551.
Vande VeldeC, MillerTM, CashmanNR, ClevelandDW. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc Natl Acad Sci U S A, 105:4022–4027. 2008.
VasilakiA, van der MeulenJH, LarkinL, HarrisonDC, PearsonT, Van RemmenH, RichardsonA, BrooksSV, JacksonMJ, McArdleA. The age-related failure of adaptive responses to contractile activity in skeletal muscle is mimicked in young mice by deletion of Cu,Zn superoxide dismutase. Aging Cell, 9:979–990. 2010.
556.
VijayvergiyaC, BealMF, BuckJ, ManfrediG. Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. J Neurosci, 25:2463–2470. 2005.
557.
VoigtA, HerholzD, FieselFC, KaurK, MullerD, KarstenP, WeberSS, KahlePJ, MarquardtT, SchulzJB. TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS One, 5:e12247. 2010.
558.
VolkeningK, Leystra-LantzC, StrongMJ. Human low molecular weight neurofilament (NFL) mRNA interacts with a predicted p190RhoGEF homologue (RGNEF) in humans. Amyotroph Lateral Scler, 11:97–103. 2010.
559.
VolkeningK, Leystra-LantzC, YangW, JaffeeH, StrongMJ. Tar DNA binding protein of 43 kDa (TDP-43), 14–3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS)Brain Res, 1305:168–182. 2009.
VukosavicS, StefanisL, Jackson-LewisV, GueganC, RomeroN, ChenC, Dubois-DauphinM, PrzedborskiS. Delaying caspase activation by Bcl-2: A clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci, 20:9119–9125. 2000.
562.
WalkerAK, AtkinJD. Stress signaling from the endoplasmic reticulum: a central player in the pathogenesis of amyotrophic lateral sclerosis. IUBMB Life, 63:754–763. 2011.
563.
WangJ, XuG, BorcheltDR. High molecular weight complexes of mutant superoxide dismutase 1: age-dependent and tissue-specific accumulation. Neurobiol Dis, 9:139–148. 2002.
564.
WangJ, XuG, LiH, GonzalesV, FromholtD, KarchC, CopelandNG, JenkinsNA, BorcheltDR. Somatodendritic accumulation of misfolded SOD1-L126Z in motor neurons mediates degeneration: alphaB-crystallin modulates aggregation. Hum Mol Genet, 14:2335–2347. 2005.
565.
WangJ, ZhangY, TangL, ZhangN, FanD. Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis. Neurosci Lett, 503:250–255. 2011.
WangL, GrisottiG, RoosRP. Mutant SOD1 knockdown in all cell types ameliorates disease in G85R SOD1 mice with a limited additional effect over knockdown restricted to motor neurons. J Neurochem, 113:166–174. 2010.
568.
WangL, GutmannD, RoosRP. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum Mol Genet, 20:286–293. 2011.
569.
WangL, PopkoB, RoosRP. The unfolded protein response in familial amyotrophic lateral sclerosis. Hum Mol Genet, 20:1008–1015. 2011.
570.
WangL, SharmaK, DengHX, SiddiqueT, GrisottiG, LiuE, RoosRP. Restricted expression of mutant SOD1 in spinal motor neurons and interneurons induces motor neuron pathology. Neurobiol Dis, 29:400–408. 2008.
571.
WangL, SharmaK, GrisottiG, RoosRP. The effect of mutant SOD1 dismutase activity on non-cell autonomous degeneration in familial amyotrophic lateral sclerosis. Neurobiol Dis, 35:234–240. 2009.
572.
WangQ, JohnsonJL, AgarNY, AgarJN. Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival. PLoS Biol, 6:e170. 2008.
573.
WangQ, ZhangX, ChenS, ZhangX, ZhangS, YoudiumM, LeW. Prevention of motor neuron degeneration by novel iron chelators in SOD1(G93A) transgenic mice of amyotrophic lateral sclerosis. Neurodegener Dis, 8:310–321. 2011.
WangX, FanH, YingZ, LiB, WangH, WangG. Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neurosci Lett, 469:112–116. 2010.
576.
WateR, ItoH, ZhangJH, OhnishiS, NakanoS, KusakaH. Expression of an endoplasmic reticulum-resident chaperone, glucose-regulated stress protein 78, in the spinal cord of a mouse model of amyotrophic lateral sclerosis. Acta Neuropathol (Berl), 110:557–562. 2005.
577.
WegorzewskaI, BellS, CairnsNJ, MillerTM, BalohRH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A, 106:18809–18814. 2009.
578.
WeihlCC, PestronkA, KimonisVE. Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia. Neuromuscul Disord, 19:308–315. 2009.
579.
WeisigerRA, FridovichI. Mitochondrial superoxide simutase. Site of synthesis and intramitochondrial localization. J Biol Chem, 248:4793–4796. 1973.
580.
WichterleH, LieberamI, PorterJA, JessellTM. Directed differentiation of embryonic stem cells into motor neurons. Cell, 110:385–397. 2002.
581.
WicksP, GanesalinghamJ, CollinC, PrevettM, LeighNP, Al-ChalabiA. Three soccer playing friends with simultaneous amyotrophic lateral sclerosis. Amyotroph Lateral Scler, 8:177–179. 2007.
582.
WilcoxKC, ZhouL, JordonJK, HuangY, YuY, RedlerRL, ChenX, CaplowM, DokholyanNV. Modifications of superoxide dismutase (SOD1) in human erythrocytes: a possible role in amyotrophic lateral sclerosis. J Biol Chem, 284:13940–13947. 2009.
583.
WilliamsAH, ValdezG, MoresiV, QiX, McAnallyJ, ElliottJL, Bassel-DubyR, SanesJR, OlsonEN. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science, 326:1549–1554. 2009.
584.
WilsH, KleinbergerG, JanssensJ, PeresonS, JorisG, CuijtI, SmitsV, Ceuterick-de GrooteC, Van BroeckhovenC, Kumar-SinghS. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A, 107:3858–3863. 2010.
585.
WitanH, KernA, Koziollek-DrechslerI, WadeR, BehlC, ClementAM. Heterodimer formation of wild-type and amyotrophic lateral sclerosis-causing mutant Cu/Zn-superoxide dismutase induces toxicity independent of protein aggregation. Hum Mol Genet, 17:1373–1385. 2008.
586.
WojciechowskaM, KrzyzosiakWJ. Cellular toxicity of expanded RNA repeats: focus on RNA foci. Hum Mol Genet, 20:3811–3821. 2011.
587.
WongM, MartinLJ. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum Mol Genet, 19:2284–2302. 2010.
588.
WuD, YuW, KishikawaH, FolkerthRD, IafrateAJ, ShenY, XinW, SimsK, HuGF. Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann Neurol, 62:609–617. 2007.
589.
XiaoS, SanelliT, DibS, ShepsD, FindlaterJ, BilbaoJ, KeithJ, ZinmanL, RogaevaE, RobertsonJ. RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS. Mol Cell Neurosci, 47:167–180. 2011.
590.
XuYF, GendronTF, ZhangYJ, LinWL, D'AltonS, ShengH, CaseyMC, TongJ, KnightJ, YuX, RademakersR, BoylanK, HuttonM, McGowanE, DicksonDW, LewisJ, PetrucelliL. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci, 30:10851–10859. 2010.
591.
YamanakaK, BoilleeS, RobertsEA, GarciaML, McAlonis-DownesM, MikseOR, ClevelandDW, GoldsteinLS. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci U S A, 105:7594–7599. 2008.
592.
YamanakaK, ChunSJ, BoilleeS, Fujimori-TonouN, YamashitaH, GutmannDH, TakahashiR, MisawaH, ClevelandDW. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci, 11:251–253. 2008.
593.
YamanakaK, MillerTM, McAlonis-DownesM, ChunSJ, ClevelandDW. Progressive spinal axonal degeneration and slowness in ALS2-deficient mice. Ann Neurol, 60:95–104. 2006.
YangC, TanW, WhittleC, QiuL, CaoL, AkbarianS, XuZ. The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism. PLoS One, 5:e15878. 2010.
596.
YangL, ChanskyHA, HicksteinDD. EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J Biol Chem, 275:37612–37618. 2000.
597.
YangY, HentatiA, DengHX, DabbaghO, SasakiT, HiranoM, HungWY, OuahchiK, YanJ, AzimAC, ColeN, GasconG, YagmourA, Ben-HamidaM, Pericak-VanceM, HentatiF, SiddiqueT. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet, 29:160–165. 2001.
598.
YasuiM, OtaK, GarrutoRM. Concentrations of zinc and iron in the brains of Guamanian patients with amyotrophic lateral sclerosis and parkinsonism-dementia. Neurotoxicology, 14:445–450. 1993.
599.
YingH, ShenX, ParkB, YueBY. Posttranslational modifications, localization, and protein interactions of optineurin, the product of a glaucoma gene. PLoS One, 5:e9168. 2010.
600.
YingZ, WangH, FanH, ZhuX, ZhouJ, FeiE, WangG. Gp78, an ER associated E3, promotes SOD1 and ataxin-3 degradation. Hum Mol Genet, 18:4268–4281. 2009.
601.
YooYE, KoCP. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis. Exp Neurol, 231:147–159. 2011.
602.
YoshiharaT, IshigakiS, YamamotoM, LiangY, NiwaJ, TakeuchiH, DoyuM, SobueG. Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem, 80:158–167. 2002.
603.
ZetterstromP, AndersenPM, BrannstromT, MarklundSL. Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral sclerosis patients. J Neurochem, 117:91–99. 2011.
604.
ZetterstromP, GraffmoKS, AndersenPM, BrannstromT, MarklundSL. Proteins that bind to misfolded mutant superoxide dismutase-1 in spinal cords from transgenic amyotrophic lateral sclerosis (ALS) model mice. J Biol Chem, 286:20130–20136. 2011.
605.
ZhangC, ZhouC, TengJJ, ZhaoRL, SongYQ, ZhangC. Multiple administrations of human marrow stromal cells through cerebrospinal fluid prolong survival in a transgenic mouse model of amyotrophic lateral sclerosis. Cytotherapy, 11:299–306. 2009.
606.
ZhangT, MullanePC, PerizG, WangJ. TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling. Hum Mol Genet, 20:1952–1965. 2011.
607.
ZhangX, LiL, ChenS, YangD, WangY, ZhangX, WangZ, LeW. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy, 7:412–425. 2011.
608.
ZhangY, ZolovSN, ChowCY, SlutskySG, RichardsonSC, PiperRC, YangB, NauJJ, WestrickRJ, MorrisonSJ, MeislerMH, WeismanLS. Loss of Vac14, a regulator of the signaling lipid phosphatidylinositol 3,5-bisphosphate, results in neurodegeneration in mice. Proc Natl Acad Sci U S A, 104:17518–17523. 2007.
609.
ZhangYJ, XuYF, CookC, GendronTF, RoettgesP, LinkCD, LinWL, TongJ, Castanedes-CaseyM, AshP, GassJ, RangachariV, BurattiE, BaralleF, GoldeTE, DicksonDW, PetrucelliL. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A, 106:7607–7612. 2009.
610.
ZhangYJ, XuYF, DickeyCA, BurattiE, BaralleF, BaileyR, Pickering-BrownS, DicksonD, PetrucelliL. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci, 27:10530–10534. 2007.
ZhongZ, IlievaH, HallaganL, BellR, SinghI, PaquetteN, ThiyagarajanM, DeaneR, FernandezJA, LaneS, ZlokovicAB, LiuT, GriffinJH, ChowN, CastellinoFJ, StojanovicK, ClevelandDW, ZlokovicBV. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest, 119:3437–3449. 2009.
614.
ZhouH, HuangC, ChenH, WangD, LandelCP, XiaPY, BowserR, LiuYJ, XiaXG. Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet, 6:e1000887. 2010.
615.
ZhuYB, ShengZH. Increased axonal mitochondrial mobility does not slow amyotrophic lateral sclerosis (ALS)-like disease in mutant SOD1 mice. J Biol Chem, 286:23432–23440. 2011.
616.
ZinmanL, CudkowiczM. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol, 10:481–490. 2011.